"#",Jurisdiction,Kind,Display Key,Lens ID,Publication Date,Publication Year,Application Number,Application Date,Priority Numbers,Earliest Priority Date,Title,Abstract,Applicants,Inventors,Owners,URL,Document Type,Has Full Text,Cites Patent Count,Cited by Patent Count,Simple Family Size,Extended Family Size,Sequence Count,CPC Classifications,IPCR Classifications,US Classifications,NPL Citation Count,NPL Resolved Citation Count,NPL Resolved Lens ID(s),NPL Resolved External ID(s),NPL Citations,Legal Status
1,US,B2,US 6701855 B2,058-825-770-472-575,2004-03-09,2004,US 45232603 A,2003-06-02,US 45232603 A;;US 38577202 P,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,"
    A process for the pyrolysis of waste materials, particularly medical waste, is provided. In the pyrolysis process, waste material is placed in a sealed container. The sealed container is placed in a load chamber and the waste material is subjected to pyrolysis. The process generates pyrolysis gases containing volatile organic compounds which are fed to an oxidation chamber containing tangential and radial air inlet ports. The pyrolysis gases are combusted and hot gases are produced in the oxidation chamber. In the operation, at least a portion of the generated heat and hot gases is fed to the load chamber which holds the pyrolysis container. 
",GLOBAL ENVIRONMENTAL TECHNOLOG,BARBA PETER DAVID,HONUA TECHNOLOGIES INC (2004-11-19);;GLOBAL ENVIRONMENTAL TECHNOLOGIES LLC (2003-05-30),https://lens.org/058-825-770-472-575,Granted Patent,yes,28,13,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,110/342;;110/230;;110/210;;110/242,0,0,,,,EXPIRED
2,WO,A2,WO 2003/102470 A2,076-953-553-554-442,2003-12-11,2003,US 0317364 W,2003-06-02,US 38577202 P,2002-06-03,PROCESS FOR THE PYROLYSIS OF MEDICAL WASTE AND OTHER WASTE MATERIALS,"A process for the pyrolysis of waste materials, particularly medical waste, is provided. In the pyrolysis process, waste material (36) is placed in a sealed container (38). The sealed container (38) is placed in a load chamber (34) and the waste material (36) is subjected to pyrolysis. The process generates pyrolysis gases containing volatile organic compounds which are fed to an oxidation chamber (14) containing tangential (20) and radial (22) air inlet ports. The pyrolysis gases are combusted and hot gases are produced in the oxidation chamber (14). In the operation, at least a portion of the generated heat and hot gases is fed to the load chamber (34) which holds the pyrolysis container (38).",GLOBAL ENVIRONMENTAL TECHNOLOG,BARBA PETER DAVID,,https://lens.org/076-953-553-554-442,Patent Application,yes,0,0,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,PENDING
3,AU,A1,AU 2003/239935 A1,078-518-243-077-202,2003-12-19,2003,AU 2003/239935 A,2003-06-02,US 38577202 P;;US 0317364 W,2002-06-03,PROCESS FOR THE PYROLYSIS OF MEDICAL WASTE AND OTHER WASTE MATERIALS,,GLOBAL ENVIRONMENTAL TECHNOLOG,BARBA PETER DAVID,,https://lens.org/078-518-243-077-202,Patent Application,no,0,0,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,DISCONTINUED
4,WO,A3,WO 2003/102470 A3,017-699-807-908-693,2004-09-16,2004,US 0317364 W,2003-06-02,US 38577202 P,2002-06-03,PROCESS FOR THE PYROLYSIS OF MEDICAL WASTE AND OTHER WASTE MATERIALS,"A process for the pyrolysis of waste materials, particularly medical waste, is provided. In the pyrolysis process, waste material (36) is placed in a sealed container (38). The sealed container (38) is placed in a load chamber (34) and the waste material (36) is subjected to pyrolysis. The process generates pyrolysis gases containing volatile organic compounds which are fed to an oxidation chamber (14) containing tangential (20) and radial (22) air inlet ports. The pyrolysis gases are combusted and hot gases are produced in the oxidation chamber (14). In the operation, at least a portion of the generated heat and hot gases is fed to the load chamber (34) which holds the pyrolysis container (38).",GLOBAL ENVIRONMENTAL TECHNOLOG,BARBA PETER DAVID,,https://lens.org/017-699-807-908-693,Search Report,yes,3,0,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,PENDING
5,TW,A,TW 200404980 A,081-486-530-093-322,2004-04-01,2004,TW 92115084 A,2003-06-03,US 38577202 P;;US 45232603 A,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,"A process for the pyrolysis of waste materials, particularly medical waste, is provided. In the pyrolysis process, waste material is placed in a sealed container. The sealed container is placed in a load chamber and the waste material is subjected to pyrolysis. The process generates pyrolysis gases containing volatile organic compounds which are fed to an oxidation chamber containing tangential and radial air inlet ports. The pyrolysis gases are combusted and hot gases are produced in the oxidation chamber. In the operation, at least a portion of the generated heat and hot gases is fed to the load chamber which holds the pyrolysis container.",GLOBAL ENVIRONMENTAL TECHNOLOGIES LLC,BARBA PETER DAVID,,https://lens.org/081-486-530-093-322,Patent of Addition,no,0,0,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,PENDING
6,AU,A8,AU 2003/239935 A8,017-660-218-775-724,2003-12-19,2003,AU 2003/239935 A,2003-06-02,US 38577202 P;;US 0317364 W,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,,GLOBAL ENVIRONMENTAL TECHNOLOG,BARBA PETER DAVID,,https://lens.org/017-660-218-775-724,Patent Application,no,0,0,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,DISCONTINUED
7,CN,A,CN 1671994 A,081-318-092-454-294,2005-09-21,2005,CN 03818507 A,2003-06-02,US 38577202 P;;US 0317364 W,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,,GLOBAL ENVIRONMENTAL TECHNOLOG,DAVID BARBA PETER,,https://lens.org/081-318-092-454-294,Patent Application,no,0,9,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,EXPIRED
8,CN,C,CN 100356103 C,106-171-895-685-83X,2007-12-19,2007,CN 03818507 A,2003-06-02,US 38577202 P;;US 0317364 W,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,,GLOBAL ENVIRONMENTAL TECHNOLOG,DAVID BARBA PETER,,https://lens.org/106-171-895-685-83X,Granted Patent,no,5,1,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23B99/00;;F23C7/00;;F23G5/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,,0,0,,,,EXPIRED
9,US,A1,US 2003/0221597 A1,007-266-680-198-594,2003-12-04,2003,US 45232603 A,2003-06-02,US 45232603 A;;US 38577202 P,2002-06-03,Process for the pyrolysis of medical waste and other waste materials,"
   A process for the pyrolysis of waste materials, particularly medical waste, is provided. In the pyrolysis process, waste material is placed in a sealed container. The sealed container is placed in a load chamber and the waste material is subjected to pyrolysis. The process generates pyrolysis gases containing volatile organic compounds which are fed to an oxidation chamber containing tangential and radial air inlet ports. The pyrolysis gases are combusted and hot gases are produced in the oxidation chamber. In the operation, at least a portion of the generated heat and hot gases is fed to the load chamber which holds the pyrolysis container. 
",BARBA PETER DAVID,BARBA PETER DAVID,HONUA TECHNOLOGIES INC (2004-11-19);;GLOBAL ENVIRONMENTAL TECHNOLOGIES LLC (2003-05-30),https://lens.org/007-266-680-198-594,Patent Application,yes,28,16,11,11,0,F23C7/002;;F23G5/0273;;F23G5/12;;F23G5/16;;F23G5/50;;F23G2207/101;;F23G2207/30;;F23G2209/20;;F23G2900/7009;;F23G5/027;;F23G5/16;;F23G5/12;;F23G5/0273;;F23G2207/101;;F23G5/50;;F23G2207/30;;F23G2209/20;;F23C7/002;;F23G2900/7009,F23C7/00;;F23G5/027;;F23G5/12;;F23G5/16;;F23G5/50,110/342;;X11023,0,0,,,,EXPIRED
10,MX,A,MX JL02000051 A,004-758-065-360-248,2004-06-30,2004,MX JL02000051 A,2002-12-19,MX JL02000051 A,2002-12-19,PLATE CONJUNCT FOR FOOD AND BEVERAGES.,"The present discloses a conjunct of plates for food and beverages destined to be used in special events. The plate conjunct consists in a first receptor section of food joined as a single piece with a second section that includes an opening practiced to hold a receptacle for beverages and one or more provided perforations or grooves to hold articles of common use for food consumption. The plate conjunct moreover incorporates a holding element to facilitate a user single-handed grasp with commodity and safety. At a preferred modality of the invention, the holding element consists in a semicircular piece placed under the plate and through it a finger could be introduced to hold and sustain said plate firmly and securely.",DAVID BARBA JAIME,DAVID BARBA JAIME,,https://lens.org/004-758-065-360-248,Patent Application,no,0,0,1,1,0,,A47G19/22,,0,0,,,,DISCONTINUED
11,WO,A1,WO 2023/118875 A1,152-297-602-241-699,2023-06-29,2023,GB 2022053355 W,2022-12-22,EP 21216843 A;;EP 22177827 A;;GB 2022052781 W,2021-12-22,PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS,"The invention relates to a compound of formula (I) which is 6-((1H-pyrazol-4-yl)sulfonyl)-2-((1-cyclopropyl-1H-pyrazol-3-yl)methyl)phthalazin-1(2H)- one; or a salt and/or solvate thereof; and to its use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder.",SITRYX THERAPEUTICS LTD,DAVID COUSIN;;OSCAR BARBA,,https://lens.org/152-297-602-241-699,Patent Application,yes,5,0,1,3,0,C07D403/14;;A61K31/502;;A61P35/00;;A61P29/00;;A61P37/02;;A61P7/00;;A61P3/04;;A61P3/10,C07D237/30;;A61K31/502;;A61P3/00;;A61P7/00;;A61P35/00;;A61P37/00;;C07D401/06;;C07D403/06;;C07D403/14;;C07D405/06;;C07D405/14;;C07D413/06;;C07D417/06;;C07D471/04;;C07D498/04,,19,10,081-868-337-966-324;;047-685-649-133-933;;100-639-577-671-128;;001-043-571-968-135;;061-327-588-183-132;;056-111-709-494-022;;055-011-899-315-245;;015-846-485-103-765;;011-447-588-130-308;;039-583-133-088-839,10.1002/jhet.1001;;10.1007/s40519-018-0481-6;;29397563;;10.1074/jbc.m112.441469;;pmc3682537;;23640882;;33054047;;32703798;;pmc7556514;;10.3324/haematol.2019.241141;;10.3892/ol.2016.4168;;pmc4774429;;26998110;;31483964;;10.1056/nejmoa1902678;;22999886;;10.1016/j.chembiol.2012.07.021;;pmc3775715;;28760888;;pmc5609468;;10.1182/blood-2016-11-753525;;10.1038/s41422-020-0291-z;;pmc7118080;;32132672;;pmc7865720;;10.3390/ijms22031171;;33503959,"XIN MINHANG ET AL: ""A General and Facile Synthesis of Novel Polysubstituted Quinazolin-4(3 H )-ones"", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 50, no. 1, 1 January 2013 (2013-01-01), US, pages 169 - 174, XP055903481, ISSN: 0022-152X, DOI: 10.1002/jhet.1001;;PUBCHEM: ""6-sulfanyl-2H-phthalazin-1-one | C8H6N2OS - PubChem"", 17 December 2019 (2019-12-17), XP093014450, Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.nih.gov/compound/142933162> [retrieved on 20230117];;THEODORA W. GREENEPETER G. M. WUTS: ""Protective Groups in Organic Synthesis"", 2006, JOHN WILEY & SONS INC;;LEWANDOWSKI ET AL., CELL METAB, vol. 32, no. 5, 2020, pages 736 - 750;;ALVES-FILHO ET AL., FRONT IMMUNOL, vol. 7, no. 145, 2016, pages 1 - 7;;BARAZZONI ET AL., EATING AND WEIGHT DISORDERS - STUDIES ON ANOREXIA, BULIMIA AND OBESITY, vol. 23, 2018, pages 149 - 157;;BETTAIEB ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 24, 2013, pages 17360 - 17371;;BIANCHI ET AL., HAEMATOLOGICA, vol. 105, no. 9, 2020, pages 2218 - 2228;;CANGADO ET AL., HEMATOLOGY, TRANSFUSION AND CELL THERAPY, vol. 40, no. 1, 2018, pages 1 - 2;;CHHIPA ET AL., LIFE SCIENCES, 2018, pages 280;;DONG ET AL., ONCOL LETT, vol. 11, no. 3, 2016, pages 1980 - 1986;;GRACE ET AL., N. ENGL. J. MED., vol. 381, no. 10, 2019, pages 933 - 944;;KUNG ET AL., CHEMISTRY & BIOLOGY, vol. 19, 2012, pages 1187 - 1198;;KUNG ET AL., BLOOD, vol. 130, no. 11, 2017, pages 1347 - 1356;;LIU ET AL., J. DIABETES INVESTIG., vol. 12, no. 5, 2020, pages 697 - 709;;PALSSON-MCDERMOTT ET AL., CELL RESEARCH, vol. 30, 2020, pages 300 - 314;;PUCKETT ET AL., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, 2021, pages 1171;;QI ET AL., NAT MED, vol. 23, no. 6, 2017, pages 753 - 762;;YI ET AL., FRONT. IMMUNOL., 2021",PENDING
12,TW,A,TW 202325288 A,179-637-127-864-368,2023-07-01,2023,TW 111142161 A,2022-11-04,EP 21206793 A;;EP 21216843 A;;EP 22177827 A,2021-11-05,Novel compounds,"The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: wherein R<SP>A</SP>, R<SP>B</SP>, R<SP>C</SP> and R<SP>D</SP>, X, Y1, Y2, Y3, Z1, Z2 and m are as defined herein.",SITRYX THERAPEUTICS LTD,COUSIN DAVID;;BARBA OSCAR,,https://lens.org/179-637-127-864-368,Patent of Addition,no,0,0,2,3,0,C07D237/30;;C07D401/06;;C07D403/06;;C07D405/06;;C07D405/14;;C07D413/06;;C07D417/06;;C07D471/04;;C07D498/04;;A61K45/06,A61K31/435;;A61K31/41;;A61K31/495;;A61K31/53;;A61K31/535;;A61K31/54;;A61P9/00;;A61P25/00;;A61P35/00;;A61P37/00,,0,0,,,,PENDING
13,WO,A1,WO 2023/079294 A1,060-861-474-428-676,2023-05-11,2023,GB 2022052781 W,2022-11-04,EP 21206793 A;;EP 21216843 A;;EP 22177827 A,2021-11-05,PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS,"The invention relates to compounds of formula (Ia) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: wherein R A , R B , R C and R D , X, Y 1 , Y 2 , Y 3 , Z 1 , Z 2 and m are as defined herein.",SITRYX THERAPEUTICS LTD,COUSIN DAVID;;BARBA OSCAR,,https://lens.org/060-861-474-428-676,Patent Application,yes,5,0,2,3,0,C07D237/30;;C07D401/06;;C07D403/06;;C07D405/06;;C07D405/14;;C07D413/06;;C07D417/06;;C07D471/04;;C07D498/04;;A61K45/06,C07D237/30;;A61K31/502;;A61P3/00;;A61P7/00;;A61P35/00;;A61P37/00;;C07D401/06;;C07D403/06;;C07D405/06;;C07D405/14;;C07D413/06;;C07D417/06;;C07D471/04;;C07D498/04,,3,1,081-868-337-966-324,10.1002/jhet.1001,"XIN MINHANG ET AL: ""A General and Facile Synthesis of Novel Polysubstituted Quinazolin-4(3 H )-ones"", JOURNAL OF HETEROCYCLIC CHEMISTRY, vol. 50, no. 1, 1 January 2013 (2013-01-01), US, pages 169 - 174, XP055903481, ISSN: 0022-152X, DOI: 10.1002/jhet.1001;;PUBCHEM: ""6-sulfanyl-2H-phthalazin-1-one | C8H6N2OS - PubChem"", 17 December 2019 (2019-12-17), XP093014450, Retrieved from the Internet <URL:https://pubchem.ncbi.nlm.nih.gov/compound/142933162> [retrieved on 20230117];;THEODORA W. GREENEPETER G. M. WUTS: ""Protective Groups in Organic Synthesis"", 2006, JOHN WILEY & SONS INC",PENDING
14,US,A,US 5529774 A,057-117-381-471-508,1996-06-25,1996,US 74433591 A,1991-08-13,US 74433591 A,1991-08-13,In vivo transfer of the HSV-TK gene implanted retroviral producer cells,"The present invention is directed to methods of transferring therapeutic genes to brain tumor cells in order to kill the cells. In general, the method of the present invention comprises: (1) introducing a retrovirus containing a selectable marker and at least one gene required for its replication into producer cells such that integration of the proviral DNA corresponding to the retrovirus into the genome of the producer cell results in the generation of a modified retrovirus wherein at least one of the genes required for replication of the retrovirus is replaced by the therapeutic gene or genes; (2) selecting producer cells in which the modified retrovirus is incorporated as part of the genome of the producer cells; (3) grafting the producer cells in proximity to the dividing tumor cell in order to infect the tumor cell with the modified retrovirus, thereby transferring the therapeutic gene or genes to the tumor cell; and (4) killing the cells by administering a substance that is metabolized by the therapeutic gene transferred to the tumor cells into a metabolite that kills the cells. Suitable retroviral vectors and methods for generating them, producer cells, and grafting methods are described.",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1991-09-13),https://lens.org/057-117-381-471-508,Granted Patent,yes,2,93,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;C12N15/09;;A61K31/70;;C12N15/867,424/93.21;;424/93.2;;424/93.6;;514/44,33,24,014-216-752-035-849;;006-305-559-179-669;;080-476-437-936-318;;144-088-417-465-606;;067-259-000-991-62X;;019-691-355-788-075;;140-473-733-245-184;;039-330-535-028-278;;019-093-808-527-127;;089-045-573-521-697;;015-018-209-065-973;;017-986-942-799-508;;014-216-752-035-849;;011-813-528-085-143;;079-973-203-378-95X;;025-253-948-550-190;;032-485-315-906-886;;000-554-592-309-823;;133-937-184-150-076;;016-774-540-058-538;;127-486-074-425-123;;167-704-985-049-548;;094-857-606-776-915;;006-305-559-179-669,10.1093/jnci/82.4.297;;2299679;;2501628;;10.1016/0169-328x(89)90061-2;;10.1126/science.1317968;;1317968;;8380127;;pmc43782;;10.1073/pnas.91.10.4348;;8183911;;1655012;;7528789;;10.1007/bf01052721;;10.1089/hum.1993.4.1-39;;8384892;;2433767;;10.1126/science.2433767;;10.1126/science.6093246;;6093246;;10.1126/science.175.4025.949;;5061866;;2573072;;pmc298422;;10.1073/pnas.86.22.9011;;10.1093/jnci/82.4.297;;2299679;;3019523;;10.1016/s0079-6123(08)60345-3;;2907815;;10.1101/sqb.1986.051.01.117;;3034493;;10.1073/pnas.84.10.3344;;3033644;;pmc304866;;10.1016/0076-6879(87)49040-x;;3480408;;2985952;;pmc366734;;10.1128/mcb.5.3.431-437.1985;;10.1128/mcb.5.3.431;;3078718;;3502707;;pmc254146;;10.1128/jvi.61.5.1639-1646.1987;;3476817;;10.1016/0092-8674(83)90344-6;;6678608;;2501628;;10.1016/0169-328x(89)90061-2,"Moolten et al (1990) J. Natl. Cancer Inst. 82, 297 300.;;Shimohama et al(1989) Molic. Brain Res. 5, 271 278.;;Culven et al (1992) Science 256, 1550 1552.;;Ram et al (1993) Cancer Res. 53, 83 88.;;Barba et al (1994) Proced. Natl. Acad. Sci 91, 4348 4352.;;Ezzeddine et al (1991) The New Biologist 3, 608 614.;;Kimler (1994) J. Neuro Oncology 20, 103 109.;;Oldfield et al (1993) Human Gene Therapy 4, 39 69.;;Comprehensive Textbook of Oncology, Moossa et al eds, Williamsa Wilkins, Baltimore, 1991, pp. 477 485 and 537 556.;;Rosenstein, Neocortical Transplants in the Mammalian Brian lack a Bloood brain Barrier to Macromolecules , Science 235: 772 774 (1987).;;Anderson, Prospects for Human Gene Therapy , Science 226:401 409 (1984).;;Friedmann et al., Gene Therapy for Human Genetic Disease , Science 175:949 955 (1972).;;Friedmann, Gene Therapy Fact and Fiction , Cold Spring Harbor Laboratory, New York (1983).;;Rosenberg et al., A New Approach to the Adoptive Immunotheraphy of Cancer with Tumor Infiltrating Lymphocytes , Science 242:1575 1578 (1988).;;Wolff et al., Grafting Fibroblasts Genetically Modified to Produce L dopa in a Rat Model of Parkinson Disease , Proc. Natl. Acad. Sci. USA 86:9011 9014 (1989) 1.;;Moolten & Wells, Curability of tumors Bearing Herpes Thymidine kinase Genes Transferred by Retroviral Vectors , J. Natl. Cancer Inst. 82:297 300 (1990).;;Moolten, Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy , Cancer Res. 46:527 581 (1986).;;Gage et al., Implantation of Genetically Engineered Cells to the Brain , Ch. 86, Progress in Brain Research, vol. 78, pp. 651 658 (1988).;;Yee et al., Gene Expression from a Transcriptionally Disabled Retroviral Vector , Cold Spring Harbor Symp. on Quant. Biol. vol. LI, pp. 1021 1026 (1986).;;Wolff et al., Expression of Retrovirally Transduced Genes in Primary Cultures of Adult Rat Hepatocytes , Proc. Natl. Acad. Sci. USA 84: 3344 3348 (1987).;;Jolly et al., High Efficiency Gene Transfer into Cells . Meth. in Enzymol. 149:10 25 (1987).;;Miller et al., Generation of Helper Free Amphotropic Retroviruses that Transduce a Dominant Acting, Methotrexate Resistant Dihydrofolate Reductase Gene , Mol. Cell. Biol. 5:431 437 (1985).;;Eglitis et al., Retroviral Vectors for Introduction of Genes into Mammalian Cells , Biotechniques 6:608 614 (1988).;;Bender et al., Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region , J. Virol. 61:1639 1646 (1987).;;Howell et al., Gene Therapy for Thioguanine Resistant Human Leukemia , Mol. Biol. Med. 4:157 168 (1987).;;Moolten & Brodeur, Proc. Am. Assoc. Cancer Res. 29:461 (1988).;;Das, Intraparenchymal Transplantation , Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 3, pp. 23 30 (1985).;;Freed, Transplantation of Tissues to the Cerebral Ventricles: methodological Details and Rate of Graft Survival , Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 4, pp. 31 40 (1985).;;Brundin et al., Intracerebral Grafts of neuronal Cell Suspensions , Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 6, pp. 51 60 (1985).;;David et al., Peripheral Nerve Transplantation Techniques to Study Axonal Regeneration from the CNS of Adult Mammals, Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 7, pp. 61 70 (1985).;;Seiger, Preparation of Immature Central Nervous System Regions for Transplantation , Neural Grafting in the Mammalian CNS, Bjorklund and Stenevi, eds., Ch. 8, pp. 71 77 (1985).;;Mann et al., Construction of a Retrovirus Packaging Mutant and its Use to Produce Helper Free Defective Retrovirus , Cell 33:153 159 (1983).;;Shimohama et al., Grafting Genetically Modified Cells into the Rat Brain: Characterises of E. coli Galactosidase as a Reporter Gene , Mol. Brain Res. 5:271 278 (1989).",EXPIRED
15,US,B1,US 6663857 B1,045-349-175-745-704,2003-12-16,2003,US 24219394 A,1994-05-13,US 24219394 A;;US 74433591 A,1991-08-13,In vivo gene transfer using implanted retroviral producer cells,"
    The present invention is directed to methods of transferring therapeutic genes to brain tumor cells in order to kill the cells. In general, the method of the present invention comprises: (1) introducing a retrovirus containing a selectable marker and at least one gene required for its replication into producer cells such that integration of the proviral DNA corresponding to the retrovirus into the genome of the producer cell results in the generation of a modified retrovirus wherein at least one of the genes required for replication of the retrovirus is replaced by the therapeutic gene or genes; (2) selecting producer cells in which the modified retrovirus is incorporated as part of the genome of the producer cells; (3) grafting the producer cells in proximity to the dividing tumor cell in order to infect the tumor cell with the modified retrovirus, thereby transferring the therapeutic gene or genes to the tumor cell; and (4) killing the cells by administering a substance that is metabolized by the therapeutic gene transferred to the tumor cells into a metabolite that kills the cells. Suitable retroviral vectors and methods for generating them, producer cells, and grafting methods are described. 
",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,REGENTS OF THE UNIVERSITY OF CALIFORNIA THE (1995-07-19),https://lens.org/045-349-175-745-704,Granted Patent,yes,4,2,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;C12N15/09;;A61K31/70;;C12N15/867,424/93.21;;424/93.6;;424/93.2;;514/44;;435/320.1,35,26,112-758-495-036-718;;030-855-054-592-446;;067-259-000-991-62X;;060-945-348-142-691;;028-509-515-246-877;;019-691-355-788-075;;117-679-081-180-169;;019-093-808-527-127;;089-045-573-521-697;;015-018-209-065-973;;005-423-291-659-864;;017-986-942-799-508;;014-216-752-035-849;;011-813-528-085-143;;079-973-203-378-95X;;025-253-948-550-190;;032-485-315-906-886;;000-554-592-309-823;;133-937-184-150-076;;016-774-540-058-538;;127-486-074-425-123;;167-704-985-049-548;;094-857-606-776-915;;006-305-559-179-669;;080-476-437-936-318;;144-088-417-465-606,8402637;;10.1089/hum.1995.6.6-763;;7548276;;pmc43782;;10.1073/pnas.91.10.4348;;8183911;;10.1056/nejm199511023331808;;7565977;;10.3109/07357909509011690;;7874574;;1655012;;2129047;;10.1002/jnr.490270322;;2433767;;10.1126/science.2433767;;10.1126/science.6093246;;6093246;;10.1126/science.175.4025.949;;5061866;;10.1126/science.3489291;;3489291;;2573072;;pmc298422;;10.1073/pnas.86.22.9011;;10.1093/jnci/82.4.297;;2299679;;3019523;;10.1016/s0079-6123(08)60345-3;;2907815;;10.1101/sqb.1986.051.01.117;;3034493;;10.1073/pnas.84.10.3344;;3033644;;pmc304866;;10.1016/0076-6879(87)49040-x;;3480408;;2985952;;pmc366734;;10.1128/mcb.5.3.431-437.1985;;10.1128/mcb.5.3.431;;3078718;;3502707;;pmc254146;;10.1128/jvi.61.5.1639-1646.1987;;3476817;;10.1016/0092-8674(83)90344-6;;6678608;;2501628;;10.1016/0169-328x(89)90061-2;;10.1126/science.1317968;;1317968;;8380127,"Huber etal (1993) Canc. Res. 53, 4619-4626.*;;Colambo et al (1995) Human Gene Therapy 6, 763-772.*;;Barba etal (1994) Proced. Nat. Acad. Sci 91, 4348-4352.*;;Muelen (1994) Pharmac. Therap. 63, 199-207.*;;Blau et al (Nov. 2, 1995) New Eng. J. Med.,1204-1207.*;;Vieweg et al (1995) Cancer Invest. 13, 193-201.*;;Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, Orkin et al, Dec. 7, 1995.*;;Moolten & Brodeur, Proc. Am. Assoc. Cancer Res. 29:461 (1988) (Exhibit 17).;;Friedmann, Gene Therapy Fact and Fiction, Cold Spring Harbor Laboratory, New York (1983) (Exhibit 18).;;Z.D. Ezzedine et al. (Jun. 1991) ""Selective killing of glioma cells in culture and in vivo by retrovirus transfer of the herpes simplex virus thymidine kinase gene"" The New Biologist 3(6):608-614.;;Short et al. (1990) ""Gene delivery to glioma cells in rat brain by grafting of a retrovirus packaging cell line:"" Journal of Neuroscience Research 27:427-433.;;Rosenstein, J.M., ""Neocortical Transplants in the Mammalian Brain Lack a Blood-Brain Barrier to Macromolecules,"" Science 235:772-774 (1987) (Exhibit 1).;;Anderson, W.F., ""Prospects for Human Gene Therapy,"" Science 226:401-409 (1984) (Exhibit 2).;;Friedmann, T. & Roblin, R., ""Gene Therapy for Human Genetic Disease?"", Science 175:949-955 (1972) (Exhibit 3).;;Rosenberg, S.A. et al., ""A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes,"" Science 233:1318-1321 (1986) (Exhibit 4).;;Wolff, J.A., et al., ""Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease,"" Proc.Natl.Acad. Sci.USA (1989) 86:9011-9014 (Exhibit 5).;;Moolten, F.L. et al., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors,"" Journal of the National Cancer Institute, REPORTS 82 (4):297-300 (1990) (Exhibit 6).;;Moolten, F.L., ""Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy,"" Cancer Research 46:5276-5281 (1986) (Exhibit 7).;;Gage, F.H. et al., ""Implantation of genetically engineered cells to the brain,"" Progress in Brain Research 78:651-658 (1988) (Exhibit 8).;;Yee, J.-K. et al., ""Gene Expression from a Transcriptionally Disabled Retroviral Vector,"" Cold Spring Harbor Symposia on Quantitative Biology 51:1021-1026 (1986) (Exhibit 9).;;Wolff, J.A. et al., ""Expression of retrovirally transduced genes in primary cultures of adult rat hepatocytes,"" Proc.Natl.Acad.Sci.USA 84:3344-3348 (1987) (Exhibit 10).;;Jolly, D.J. et al., ""Cell Targeting Techniques-High Efficiency Gene Transfer into Cells"" Methods In Enzymology 149:10-25 (1987) (Exhibit 11).;;Miller, A.D. et al., ""Generation of Helper-Free Amphotropic Reroviruses That Transduce a Dominant-Acting, Methotrexate-Resistant Dihydrofolate Reductase Gene,"" Molecular And Cellular Biology 5(3):431-437 (1985) (Exhibit 12).;;Eglitis, M.A. & Anderson, W.F., ""Retroviral Vectors for Introduction of Genes into Mammalian Cells,"" BioTechniques 6(7):608-614 (1988) (Exhibit 13).;;Bender, M.A. et al., ""Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region,"" Journal Of Virology 61(5):1639-1646 (1987) (Exhibit 14).;;Howell, S.B. et al., ""Gene Therapy for Thioguanine-resistant Human Leukemia,"" Mol.Biol.Med. 4:157-168 (1987) (Exhibit 15).;;Das, G.D., ""Intraparenchymal Transplantation,"" Neural Grafting in the Mammalian CNS 3:23-30 (1985) (Exhibit 16).;;Freed, W.J., ""Transplantation of Tissues to the Cerebral Venricles: Methodological Details and Rate of Graft Survival,"" Neural Grafting in the Mammalian CNS 4:31-40 (1985) (Exhibit 17).;;Brundin, P. et al., ""Intracerebral Grafts of Neuronal Cell Suspensions,"" Neural Grafting in the Mammalian CNS 6:51-59 (1985) (Exhibit 18).;;David, S. & Aguayo, A.J., ""Peripheral Nerve Transplantation Techniques to Study Axonal Regeneration From the CNS of Adult Mammals,"" Neural Grafting in the Mammalian CNS 7:61-69 (1985) (Exhibit 19).;;Seiger, A., ""Preparation of Immature Central Nervous System Regions for Transplantation,"" Neural Grafting in the Mammalian CNS 8:71-77 (1985).;;Mann, R. et al., ""Construction of Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus,"" Cell 153-159 (1983) (Exhibit 21).;;Shimohama, S. et al., Grafting genetically modified cells into the rat brain: characteristics of E coli beta-galactosidase as a reporter gene (1989) 5:271-278 (Exhibit 22).;;Culver , K.W. et al., ""In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumor,"" Science 256:1550-1552 (1992) (Exhibit 23).;;Ram, Z. et al., ""In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats,"" Cancer Research 53:83-88 (1993) (Exhibit 24).",EXPIRED
16,US,B1,US 6655898 B1,085-003-651-642-371,2003-12-02,2003,US 1476501 A,2001-12-11,US 1476501 A,2001-12-11,Front opening unified pod (FOUP) hoist jig,"
    An apparatus and method for simultaneously cycle-testing two wafer storage containers is provided. The two wafer containers are maintained in a counterbalance relationship to each other and cycled in a vertical up-and-down motion to simulate the forces of a selected overhead transport system. 
",NEC ELECTRONICS INC,LIU-BARBA DAVID;;TONG SIMON,RENESAS ELECTRONICS AMERICA INC (2010-04-01);;NEC ELECTRONICS INC (2001-12-10),https://lens.org/085-003-651-642-371,Granted Patent,yes,4,11,1,1,0,H01L21/67766;;H01L21/67769;;Y10S414/135;;Y10S414/14;;H01L21/67769;;H01L21/67766;;Y10S414/135;;Y10S414/14,B65G49/07;;H01L21/677,414/673;;414/935;;414/940;;187/404,1,0,,,"Overhead Handling Versus PWP F300 and AutoPod(TM) Wafer Carrier, EFIX, Apr. 2000; 2 pages. (Copy Enclosed).",EXPIRED
17,WO,A1,WO 1993/004167 A1,197-461-684-597-369,1993-03-04,1993,US 9206790 W,1992-08-12,US 74433591 A,1991-08-13,IN VIVO GENE TRANSFER USING IMPLANTED RETROVIRAL PRODUCER CELLS,"The present invention is directed to methods of transferring therapeutic genes to brain tumor cells in order to kill the cells. In general, the method of the present invention comprises: (1) introducing a retrovirus containing a selectable marker and at least one gene required for its replication into producer cells such that integration of the proviral DNA corresponding to the retrovirus into the genome of the producer cell results in the generation of a modified retrovirus wherein at least one of the genes required for replication of the retrovirus is replaced by the therapeutic gene or genes; (2) selecting producer cells in which the modified retrovirus is incorporated as part of the genome of the producer cells; (3) grafting the producer cells in proximity to the dividing tumor cell in order to infect the tumor cell with the modified retrovirus, thereby transferring the therapeutic gene or genes to the tumor cell; and (4) killing the cells by administering a substance that is metabolized by the therapeutic gene transferred to the tumor cells into a metabolite that kills the cells. Suitable retroviral vectors and methods for generating them, producer cells, and grafting methods are described.",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,,https://lens.org/197-461-684-597-369,Patent Application,yes,0,38,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;A61K31/70;;C12N15/09;;C12N15/867,,3,2,014-216-752-035-849;;006-305-559-179-669,10.1093/jnci/82.4.297;;2299679;;2501628;;10.1016/0169-328x(89)90061-2,"Journal of the National Cancer Institute, Volume 82, Number 4, issued 21 February 1992, F.L. MOOLTEN et al., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors"", pages 297-300, see entire document, especially page 299, table 2.;;Molecular Brain Research, Volume 5, issued 1989, S. SHIMOHAMA et al., ""Grafting Genetically Modified Cells into the Rat Brain: Characteristics of E. coli beta-Galacto-sidase as a Reporter Gene"", pages 271-278, see entire document, especially ""Discussion"".;;See also references of EP 0602118A4",PENDING
18,EP,A1,EP 0602118 A1,029-138-963-546-765,1994-06-22,1994,EP 92918569 A,1992-08-12,US 9206790 W;;US 74433591 A,1991-08-13,-i(IN VIVO) GENE TRANSFER USING IMPLANTED RETROVIRAL PRODUCER CELLS.,"Cette invention concerne des procédés permettant de transférer des gènes thérapeutiques dans des cellules tumorales du cerveau afin de tirer ces cellules. Dans ce procédé (1) on introduit un rétrovirus contenant un traceur sélectionnable et au moins un gène nécessaire pour sa réplication dans des cellules productrices de sorte que l'intégration de l'ADN proviral correspondant au rétrovirus dans le génome de la cellule productrice provoque la création d'un rétrovirus modifié dans lequel au moins un des gènes nécessaires pour la réplication du rétrovirus est remplacé par le ou les gènes thérapeutiques; (2) on sélectionne des cellules productrices dans lesquelles le rétrovirus modifié est incorporé comme faisant partie du génome des cellules productrices; (3) on greffe les cellules productrices à proximité de la cellule tumorale diviseuse afin d'infecter la cellule tumorale avec le retrovirus modifié, et on transfère ainsi le ou les gènes thérapeutiques dans la cellule tumorale; et (4) on tue les cellules en administrant une substance qui est métabolisée par le gène thérapeutique transféré dans les cellules tumorales, sous forme d'un métabolite qui tue les cellules. Cette invention concerne également des vecteurs de retrovirus appropriés et des procédés permettant de les produire, des cellules productrices et des procédés de greffe.",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,,https://lens.org/029-138-963-546-765,Patent Application,yes,0,1,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;A61K31/70;;C12N15/09;;C12N15/867,,0,0,,,,DISCONTINUED
19,CA,A1,CA 2115262 A1,144-647-535-998-321,1993-03-04,1993,CA 2115262 A,1992-08-12,US 74433591 A,1991-08-13,IN-VIVO GENE TRANSFER USING IMPLANTED RETROVIRAL PRODUCER CELLS,"2115262 9304167 PCTABS00020 The present invention is directed to methods of transferring therapeutic genes to brain tumor cells in order to kill the cells. In general, the method of the present invention comprises: (1) introducing a retrovirus containing a selectable marker and at least one gene required for its replication into producer cells such that integration of the proviral DNA corresponding to the retrovirus into the genome of the producer cell results in the generation of a modified retrovirus wherein at least one of the genes required for replication of the retrovirus is replaced by the therapeutic gene or genes; (2) selecting producer cells in which the modified retrovirus is incorporated as part of the genome of the producer cells; (3) grafting the producer cells in proximity to the dividing tumor cell in order to infect the tumor cell with the modified retrovirus, thereby transferring the therapeutic gene or genes to the tumor cell; and (4) killing the cells by administering a substance that is metabolized by the therapeutic gene transferred to the tumor cells into a metabolite that kills the cells. Suitable retroviral vectors and methods for generating them, producer cells, and grafting methods are described.",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,,https://lens.org/144-647-535-998-321,Patent Application,no,0,1,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K31/70;;A61K38/45;;A61K48/00;;A61P35/00;;C12N15/09;;C12N15/867,,0,0,,,,DISCONTINUED
20,US,B1,US 6663858 B1,141-286-870-934-181,2003-12-16,2003,US 46841195 A,1995-06-05,US 46841195 A;;US 24219394 A;;US 74433591 A,1991-08-13,In Vivo gene transfer using implanted retroviral producer cells,"
    The present invention is directed to methods of transferring therapeutic genes to brain tumor cells in order to kill the cells. In general, the method of the present invention comprises: (1) introducing a retrovirus containing a selectable marker and at least one gene required for its replication into producer cells such- that integration of the proviral DNA corresponding to the retrovirus into the genome of the producer cell results in the generation of a modified retrovirus wherein at least one of the genes required for replication of the retrovirus is replaced by the therapeutic gene or genes; (2) selecting producer cells in which the modified retrovirus is incorporated as part of the genome of the producer cells; (3) grafting the producer cells in proximity to the dividing tumor cell in order to infect the tumor cell with the modified retrovirus, thereby transferring the therapeutic gene or genes to the tumor cell; and (4) killing the cells by administering a substance that is metabolized by the therapeutic gene transferred to the tumor cells into a metabolite that kills the cells. Suitable retroviral vectors and methods for generating them, producer cells, and grafting methods are described. 
",UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,,https://lens.org/141-286-870-934-181,Granted Patent,yes,4,3,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;C12N15/09;;A61K31/70;;C12N15/867,424/93.21;;424/93.6;;424/93.2;;514/44;;435/320.1,39,28,023-229-492-349-17X;;023-229-492-349-17X;;073-685-885-892-301;;112-758-495-036-718;;030-855-054-592-446;;080-476-437-936-318;;019-093-808-527-127;;089-045-573-521-697;;015-018-209-065-973;;005-423-291-659-864;;017-986-942-799-508;;014-216-752-035-849;;011-813-528-085-143;;079-973-203-378-95X;;025-253-948-550-190;;032-485-315-906-886;;000-554-592-309-823;;133-937-184-150-076;;016-774-540-058-538;;127-486-074-425-123;;167-704-985-049-548;;094-857-606-776-915;;006-305-559-179-669;;080-476-437-936-318;;144-088-417-465-606;;019-691-355-788-075;;117-679-081-180-169;;067-259-000-991-62X,7809180;;10.1016/0163-7258(94)90046-9;;7809180;;10.1016/0163-7258(94)90046-9;;1347590;;10.1016/0140-6736(92)90606-4;;8402637;;10.1089/hum.1995.6.6-763;;7548276;;10.1126/science.1317968;;1317968;;2433767;;10.1126/science.2433767;;10.1126/science.6093246;;6093246;;10.1126/science.175.4025.949;;5061866;;10.1126/science.3489291;;3489291;;2573072;;pmc298422;;10.1073/pnas.86.22.9011;;10.1093/jnci/82.4.297;;2299679;;3019523;;10.1016/s0079-6123(08)60345-3;;2907815;;10.1101/sqb.1986.051.01.117;;3034493;;10.1073/pnas.84.10.3344;;3033644;;pmc304866;;10.1016/0076-6879(87)49040-x;;3480408;;2985952;;pmc366734;;10.1128/mcb.5.3.431-437.1985;;10.1128/mcb.5.3.431;;3078718;;3502707;;pmc254146;;10.1128/jvi.61.5.1639-1646.1987;;3476817;;10.1016/0092-8674(83)90344-6;;6678608;;2501628;;10.1016/0169-328x(89)90061-2;;10.1126/science.1317968;;1317968;;8380127;;1655012;;2129047;;10.1002/jnr.490270322;;pmc43782;;10.1073/pnas.91.10.4348;;8183911,"Mullen (1994) Pharmac. Therap. 63, 199-207.*;;Blau et al. (Nov. 2, 1995) New Eng. J. Med., 1204-107.*;;Mullen (1994) Pharmac. Ther. 63, 199-207.*;;Gutierrez et al (1992) The Lancet 339, 715-721.*;;Orkin et al al (1995) Report and Recommendations of the Panel to Asses the NIH Investment in Research on Gene Therapy.*;;Huber et al (1993) Canc. Res. 53, 4619-4626.*;;Colombo et al (1995) Human Gene Therapy 6, 763-772 (cited in patent 08/242,193).*;;Barba et al (1994) Proced. Natl. Acad. Sci. 91, 4348-4352. (cited in patent 08/242,193).*;;Culver et al (1992) Science 256, 1550-1552. (cited in patent 08/242,193).*;;Ram et al (1993) Canc. Res. 53, 83-88. (cited in patent 08/242,193).*;;Rosenstein, J.M., ""Neocortical Transplants in the Mammalian Brain Lack a Blood-Brain Barrier to Macromolecules,"" Science 235:772-774 (1987) (Exhibit 1).;;Anderson, W.F., ""Prospects for Human Gene Therapy,"" Science 226:401-409 (1984) (Exhibit 2).;;Friedmann, T. & Roblin, R., ""Gene Therapy for Human Genetic Disease?"", Science 175:949-955 (1972) (Exhibit 3).;;Rosenberg, S.A. et al., ""A New Approach to the Adoptive Immunotherapy of Cancer With Tumor-Infiltrating Lymphocytes,"" Science 233:1318-1321 (1986) (Exhibit 4).;;Wolff, J.A., et al., ""Grafting fibroblasts genetically modified to produce L-dopa in a rat model of Parkinson disease,"" Proc.Natl.Acad.Sci.USA (1989) 86:9011-9014 (Exhibit 5).;;Moolten, F.L. et al., ""Curability of Tumors Bearing Herpes Thymidine Kinase Genes Transferred by Retroviral Vectors,"" Journal of the National Cancer Institute, Reports 82 (4):297-300 (1990) (Exhibit 6).;;Moolten, F.L., ""Tumor Chemosensitivity Conferred by Inserted Herpes Thymidine Kinase Genes: Paradigm for a Prospective Cancer Control Strategy,"" Cancer Research 46:5276-5281 (1986) (Exhibit 7).;;Gage, F.H. et al., ""Implantation of genetically engineered cells to the brain,"" Progress in Brain Research 78:651-658 (1988) (Exhibit 8).;;Yee, J.-K. et al., ""Gene Expression from a Transcriptionally Disabled Retroviral Vector,"" Cold Spring Harbor Symposia on Quantitative Biology 51:1021-1026 (1986) (Exhibit 9).;;Wolff, J.A. et al., ""Expression of retrovirally transduced genes in primary cultures of adult rat hepatocytes,"" Proc.Natl.Acad.Sci.USA 84:3344-3348 (1987) (Exhibit 10).;;Jolly, D.J. et al., ""Cell Targeting Techniques-High Efficiency Gene Transfer into Cells"" Methods in Enzymology 149:10-25 (1987) (Exhibit 11).;;Miller, A.D. et al., ""Generation of Helper-Free Amphotropic Retroviruses That Transduce a Dominant-Acting, Methotrexate-Resistant Dihydrofolate Reductase Gene,"" Molecular and Cellular Biology 5(3):431-437 (1985) (Exhibit 12).;;Eglitis, M.A. & Anderson, W.F., ""Retroviral Vectors for Introduction of Genes into Mammalian Cells,"" BioTechniques 6(7):608-614 (1988) (Exhibit 13).;;Bender, M.A. et al., ""Evidence that the Packaging Signal of Moloney Murine Leukemia Virus Extends into the gag Region,"" Journal of Virology 61(5):1639-1646 (1987) (Exhibit 14).;;Howell, S.B. et al., ""Gene Therapy for Thioguanine-resistant Human Leukemia,"" Mol.Biol.Med. 4:157-168 (1987) (Exhibit 15).;;Das, G.D., ""Intraparenchymal Transplantation,"" Neural Grafting in the Mammalian CNS 3:23-30 (1985) (Exhibit 16).;;Freed, W.J., ""Transplantation of Tissues to the Cerebral Ventricles: Methodological Details and Rate of Graft Survival,"" Neural Grafting in the Mammalian CNS 4:31-40 (1985) (Exhibit 17).;;Brundin, P. et al., ""Intracerebral Grafts of Neuronal Cell Suspensions,"" Neural Grafting in the Mammalian CNS 6:51-59 (1985) (Exhibit 18).;;David, S. & Aguayo, A.J., ""Peripheral Nerve Transplantation Techniques to Study Axonal Regeneration From the CNS of Adult Mammals,"" Neural Grafting in the Mammalian CNS 7:61-69 (1985) (Exhibit 19).;;Seiger, A., ""Preparation of Immature Central Nervous System Regions for Transplantation,"" Neural Grafting in the Mammalian CNS 8:71-77 (1985) (Exhibit 20).;;Mann, R. et al., ""Construction of Retrovirus Packaging Mutant and Its Use to Produce Helper-Free Defective Retrovirus,"" Cell 153-159 (1983) (Exhibit 21).;;Shimohama, S. et al., Grafting genetically modified cells into the rat brain: characteristics of E. coli beta-galactosidase as a reporter gene (1989) 5:271-278 (Exhibit 22).;;Culver, K.W. et al., ""In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors,"" Science 256:1550-1552 (1992) (Exhibit 23).;;Ram, Z. et al., ""In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats,"" Cancer Research 53:83-88 (1993) (Exhibit 24).;;Z.D. Ezzedine et al. (Jun. 1991) ""Selective Killing of Glioma Cells in Culture and in Vivo by Retrovirus Transfer of the Herpes Simplex Virus Tymidine Kinase Gene"" The New Biologist 3(6):608-614. (Exhibit 25).;;Short et al. (1990) ""Gene Delivery to Glioma Cells in Rat Brain by Grafting of a Retrovirus Packaging Cell Line,"" Journal of Neuroscience Research 27:427-433 (Exhibit 26).;;Moolten & Brodeur, Proc. Am. Assoc. Cancer Res. 29:461 (1988) (Exhibit 17).;;Friedmann, Gene Therapy Fact and Fiction, Cold Spring Harbor Laboratory, New York (1983) (Exhibit 18).;;Barba et al., Proc. Natl. Acad. Sci. USA, 91:4348-4352 (1994) (Exhibit 19).",EXPIRED
21,EP,A4,EP 0602118 A4,056-137-815-020-264,1996-02-28,1996,EP 92918569 A,1992-08-12,US 9206790 W;;US 74433591 A,1991-08-13,-i(IN VIVO) GENE TRANSFER USING IMPLANTED RETROVIRAL PRODUCER CELLS.,,UNIV CALIFORNIA,BARBA DAVID;;GAGE FRED H,,https://lens.org/056-137-815-020-264,Search Report,no,2,1,8,8,0,A61K48/00;;C12N15/86;;C12N2740/13043;;A61P35/00;;C12N15/86;;C12N2740/13043;;A61K48/00,A61K38/45;;A61K48/00;;A61P35/00;;A61K31/70;;C12N15/09;;C12N15/867,,5,4,011-813-528-085-143;;117-679-081-180-169;;127-486-074-425-123;;080-476-437-936-318,3019523;;2129047;;10.1002/jnr.490270322;;3502707;;pmc254146;;10.1128/jvi.61.5.1639-1646.1987;;10.1126/science.1317968;;1317968,"MOOLTEN: ""TUMOR CHEMOSENSITIVITY CONFERRED BY INSERTED HERPES THYMIDINE KINASE GENES:PARADIGM FOR A PROSPECTIVE CANCER CONTROL STRATEGY"", CANCER RESEARCH, vol. 46, no. 10, pages 5276 - 5281;;DATABASE MEDLINE FILE SERVER STN KARLSRUHE; SHORT ET AL: ""GENE DELIVERY TO GLIOMA CELLS IN RAT BRAIN BY GRAFTING OF A RETROVIRUS PACKAGING CELL LINE"";;BENDER ET AL: ""EVIDENCE THAT THE PACKAGING SIGNAL OF MOLONEY MURINE LEUKEMIA VIRUS EXTENDS INTO THE GAG REGION"", JOURNAL OF VIROLOGY, vol. 61, no. 5, pages 1639 - 646, XP002036903;;CULVER ET AL: ""IN VIVO GENE TRANSFER WITH RETROVIRAL VECTOR-PRODUCER CELLS FOR TREATMENT OF EXPERIMENTAL BRAIN TUMORS"", SCIENCE, vol. 256, 12 June 1992 (1992-06-12), pages 1550 - 1552, XP002088505, DOI: doi:10.1126/science.1317968;;See also references of WO 9304167A1",DISCONTINUED
22,WO,A1,WO 2023/052783 A1,127-687-130-228-222,2023-04-06,2023,GB 2022052482 W,2022-09-30,EP 21200374 A,2021-09-30,NOVEL COMPOUNDS,"The invention relates to compounds of formula (la) and to their use in treating or preventing an inflammatory disease, a disease associated with an undesirable immune response, cancer, obesity, a diabetic disease or a blood disorder: Formula (Ia) wherein R A , R B , R C and R D , X, m and n are as defined herein.",SITRYX THERAPEUTICS LTD,COUSIN DAVID;;FYFE MATTHEW COLIN THOR;;BARBA OSCAR,,https://lens.org/127-687-130-228-222,Patent Application,yes,6,0,1,1,0,C07D471/12;;A61P29/00;;A61P37/00;;A61P35/00;;A61P7/00;;A61P3/04;;A61P3/10,C07D471/12;;A61K31/5025;;A61P3/04;;A61P3/10;;A61P7/00;;A61P29/00;;A61P35/00;;A61P37/00,,20,12,036-055-638-643-799;;025-459-899-873-738;;048-035-532-230-301;;047-685-649-133-933;;100-639-577-671-128;;001-043-571-968-135;;061-327-588-183-132;;056-111-709-494-022;;055-011-899-315-245;;015-846-485-103-765;;011-447-588-130-308;;039-583-133-088-839,10.1016/j.bmcl.2010.04.015;;20451379;;pmc2874658;;10.1016/j.ejmech.2012.09.001;;23063566;;10.1007/s00044-015-1473-y;;10.1007/s40519-018-0481-6;;29397563;;10.1074/jbc.m112.441469;;pmc3682537;;23640882;;33054047;;32703798;;pmc7556514;;10.3324/haematol.2019.241141;;10.3892/ol.2016.4168;;pmc4774429;;26998110;;31483964;;10.1056/nejmoa1902678;;22999886;;10.1016/j.chembiol.2012.07.021;;pmc3775715;;28760888;;pmc5609468;;10.1182/blood-2016-11-753525;;10.1038/s41422-020-0291-z;;pmc7118080;;32132672;;pmc7865720;;10.3390/ijms22031171;;33503959,"JIAN-KANG JIANG ET AL: ""Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 20, no. 11, 11 April 2010 (2010-04-11), pages 3387 - 3393, XP055039623, ISSN: 0960-894X, DOI: 10.1016/j.bmcl.2010.04.015;;BRUEL AMÉLIE ET AL: ""Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3K[alpha] inhibitors"", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 57, 10 September 2012 (2012-09-10), AMSTERDAM, NL, pages 225 - 233, XP055866863, ISSN: 0223-5234, DOI: 10.1016/j.ejmech.2012.09.001;;PANATHUR NAVEEN ET AL: ""Synthesis of novel 5-[(1,2,3-triazol-4-yl)methyl]-1-methyl-3H-pyridazino[4,5-b]indol-4-one derivatives by click reaction and exploration of their anticancer activity"", MEDICINAL CHEMISTRY RESEARCH, BIRKHAEUSER, BOSTON, US, vol. 25, no. 1, 5 October 2015 (2015-10-05), pages 135 - 148, XP035802895, ISSN: 1054-2523, [retrieved on 20151005], DOI: 10.1007/S00044-015-1473-Y;;""Protective Groups in Organic Synthesis"", 2006, JOHN WILEY & SONS INC;;LEWANDOWSK ET AL., CELL METAB., vol. 32, no. 5, 2020, pages 736 - 750;;ALVES-FILHO ET AL., FRONT IMMUNOL, vol. 7, no. 145, 2016, pages 1 - 7;;BARAZZONI ET AL.: ""Eating and Weight Disorders"", STUDIES ON ANOREXIA, BULIMIA AND OBESITY, vol. 23, 2018, pages 149 - 157;;BETTAIEB ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 24, 2013, pages 17360 - 17371;;BIANCHI ET AL., HAEMATOLOGICA, vol. 105, no. 9, 2020, pages 2218 - 2228;;CANGADO ET AL., HEMATOLOGY, TRANSFUSION AND CELL THERAPY, vol. 40, no. 1, 2018, pages 1 - 2;;CHHIPA ET AL., LIFE SCIENCES, vol. 280, 2018;;DONG ET AL., ONCOL LETT, vol. 11, no. 3, 2016, pages 1980 - 1986;;GRACE ET AL., N. ENGL. J. MED., vol. 381, no. 10, 2019, pages 933 - 944;;KUNG ET AL., CHEMISTRY & BIOLOGY, vol. 19, 2012, pages 1187 - 1198;;KUNG ET AL., BLOOD, vol. 130, no. 11, 2017, pages 1347 - 1356;;LIU ET AL., J. DIABETES INVESTIG, vol. 12, no. 5, 2020, pages 697 - 709;;PALSSON-MCDERMOTT ET AL., CELL RESEARCH, vol. 30, 2020, pages 300 - 314;;PUCKETT ET AL., INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, 2021, pages 1171;;QI ET AL., NAT MED., vol. 23, no. 6, 2017, pages 753 - 762;;YI ET AL., FRONT. IMMUNOL, 2021",PENDING
23,MX,A,MX 2012012037 A,180-847-519-979-261,2014-05-01,2014,MX 2012012037 A,2012-10-16,MX 2012012037 A,2012-10-16,CARTILAGE ACELLULAR SCAFFOLD AND METHOD FOR OBTAINING THE SAME.,"Described is a method for the descellularization of cartilaginous tissues and/or organs, which may be used in tissue engineering (cartilage engineering), for replacing or repairing cartilaginous tissues such as trachea, nose, ears, osteochondral cartilage. This method allows an extracellular matrix with no cells to be obtained; so that the immune response of the host organ or tissue is reduced thus it can be used in heterologous transplant, homotransplant and autologous transplant.",UNIV NAC AUTÓNOMA DE MÉXICO,BARBA MARIA CRISTINA PIÑA;;GÓMEZ DAVID MAURICIO GIRALDO,,https://lens.org/180-847-519-979-261,Patent Application,no,0,0,2,2,0,,A61K35/32,,0,0,,,,ACTIVE
24,MX,B,MX 354036 B,125-877-538-436-695,2018-01-24,2018,MX 2012012037 A,2012-10-16,MX 2012012037 A,2012-10-16,CARTILAGE ACELLULAR SCAFFOLD AND METHOD FOR OBTAINING THE SAME.,"Described is a method for the descellularization of cartilaginous tissues and/or organs, which may be used in tissue engineering (cartilage engineering), for replacing or repairing cartilaginous tissues such as trachea, nose, ears, osteochondral cartilage. This method allows an extracellular matrix with no cells to be obtained; so that the immune response of the host organ or tissue is reduced thus it can be used in heterologous transplant, homotransplant and autologous transplant.",UNIV MEXICO NAC AUTONOMA,MARIA CRISTINA PIÑA BARBA;;DAVID MAURICIO GIRALDO GÓMEZ,,https://lens.org/125-877-538-436-695,Granted Patent,no,0,0,2,2,0,,A61L27/36;;A61L27/30,,0,0,,,,ACTIVE
25,US,B1,US 6212445 B1,057-946-425-122-94X,2001-04-03,2001,US 17516898 A,1998-10-20,US 17516898 A;;US 74082296 A,1996-11-04,Vibration control system,"Methods and apparatus for generating a linear vibratory output force having a variable amplitude. The force is generated by the cooperation of four rotating eccentric masses that are grouped in two pairs of two masses. The masses in each pair are counter-rotating (i.e., they rotate at the same speed but in opposite directions). The phase relationship between the two pairs is adjustable. For example, the phase of one pair can be advanced while the phase of the other pair is retarded by an equal amount, thereby changing the amplitude of the output force without changing the direction along which the force acts, and also without changing its frequency if desired.",SMITHS IND ACTUATION SYSTEMS I,BARBA VALENTIN G;;CROOK DAVID J C;;SHUBE EUGENE E,GE AVIATION SYSTEMS LLC (2007-11-04);;WHIPPANY ACTUATION SYSTEMS LLC (2013-06-28);;SMITHS INDUSTRIES ACTUATION SYSTEMS INC (2000-03-20),https://lens.org/057-946-425-122-94X,Granted Patent,yes,8,50,3,3,0,B06B1/166;;F16F15/02;;F16F15/22;;G05D19/02;;Y10T74/18344;;Y10T74/18552;;Y10T74/18344;;Y10T74/18552;;B06B1/166;;F16F15/22;;G05D19/02;;F16F15/02,B06B1/16;;F16F15/02;;F16F15/22;;G05D19/02,700/280;;702/41;;702/56,1,0,,,English langauage translation of WO 91/08842.,EXPIRED
26,EP,A1,EP 0840191 A1,085-403-190-530-731,1998-05-06,1998,EP 97308579 A,1997-10-28,US 74082296 A,1996-11-04,Vibration control system,"Methods and apparatus for generating a linear vibratory output force having a variable amplitude. The force is generated by the cooperation of four rotating eccentric masses that are grouped in two pairs of two masses. The masses in each pair are counter-rotating (i.e., they rotate at the same speed but in opposite directions). The phase relationship between the two pairs is adjustable. For example, the phase of one pair can be advanced while the phase of the other pair is retarded by an equal amount, thereby changing the amplitude of the output force without changing the direction along which the force acts, and also without changing its frequency if desired.",GEC MARCONI AEROSPACE INC,BARBA VALENTIN G;;CROOK DAVID J C;;SHUBE EUGENE E,SMITHS INDUSTRIES ACTUATIONS SYSTEMS INC. (2000-11-29),https://lens.org/085-403-190-530-731,Patent Application,yes,4,27,3,3,0,B06B1/166;;F16F15/02;;F16F15/22;;G05D19/02;;Y10T74/18344;;Y10T74/18552;;Y10T74/18344;;Y10T74/18552;;B06B1/166;;F16F15/22;;G05D19/02;;F16F15/02,B06B1/16;;F16F15/02;;F16F15/22;;G05D19/02,,0,0,,,,DISCONTINUED
27,US,A,US 5825663 A,124-810-282-710-124,1998-10-20,1998,US 74082296 A,1996-11-04,US 74082296 A,1996-11-04,Vibration control system,"Methods and apparatus for generating a linear vibratory output force having a variable amplitude. The force is generated by the cooperation of four rotating eccentric masses that are grouped in two pairs of two masses. The masses in each pair are counter-rotating (i.e., they rotate at the same speed but in opposite directions). The phase relationship between the two pairs is adjustable. For example, the phase of one pair can be advanced while the phase of the other pair is retarded by an equal amount, thereby changing the amplitude of the output force without changing the direction along which the force acts, and also without changing its frequency if desired.",GEC MARCONI AEROSPACE INC,BARBA VALENTIN G;;CROOK DAVID J C;;SHUBE EUGENE E,GE AVIATION SYSTEMS LLC (2007-11-04);;WHIPPANY ACTUATION SYSTEMS LLC (2013-06-28);;SMITHS INDUSTRIES ACTUATION SYSTEMS INC (2000-03-20),https://lens.org/124-810-282-710-124,Granted Patent,yes,7,56,3,3,0,B06B1/166;;F16F15/02;;F16F15/22;;G05D19/02;;Y10T74/18344;;Y10T74/18552;;Y10T74/18344;;Y10T74/18552;;B06B1/166;;F16F15/22;;G05D19/02;;F16F15/02,B06B1/16;;F16F15/02;;F16F15/22;;G05D19/02,364/508;;74/61;;74/87,0,0,,,,EXPIRED
28,CN,U,CN 205239123 U,013-050-972-868-478,2016-05-18,2016,CN 201521028883 U,2015-12-10,US 201414567188 A,2014-12-11,Striking absorption system and battery support piece,"The utility model provides a 2nd sill plate that striking absorption system includes a sill plate and spaced apart with a sill plate, casing, casing include bottom of extending and the lateral part that extends from the bottom between a sill plate and the 2nd sill plate, and energy absorption spare, energy absorption spare can warp and be formed with the unit of repetition pattern for the lateral part. Energy absorption spare combines between a lateral part and a sill plate to the lateral part and every unit has transversely in the the central axis of lateral part. The utility model also provides a battery support piece. The utility model aims to provide a striking absorption system and battery support piece absorbs the striking energy with at least realization and can effectively avoid the packing restriction of battery during vehicle collision.",FORD GLOBAL TECH LLC,SAYID DAVID BARBA;;WILLIAM L STAHNKE;;MOHAMMED RIDA BACCOUCHE;;RAHUL AROLAS,,https://lens.org/013-050-972-868-478,Limited Patent,no,0,5,6,6,0,B60K1/04;;B60R19/42;;B60K2001/0438;;B60Y2306/01;;H01M2220/20;;B60L50/66;;Y02T10/70;;Y02E60/10;;H01M50/24;;H01M50/242;;B60K1/04;;B60R19/42;;B60K2001/0438;;B60Y2306/01;;H01M2220/20;;B60L50/66;;H01M50/24;;H01M50/242;;B62D21/15,B60K1/04;;B60J5/04;;B60R19/02;;H01M50/242,,0,0,,,,ACTIVE
29,WO,A1,WO 2011/128395 A1,159-225-211-290-591,2011-10-20,2011,EP 2011055865 W,2011-04-13,GB 201006167 A,2010-04-14,N- SUBSTITUTED 3-AMINO 4 - ( PYRROLIDINE - 1 - CARBONYL) PYRROLIDINE AND ITS DERIVATIVES FOR USE IN THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes. The compounds may also inhibit DPP-IV enzyme activity.,PROSIDION LTD;;BARBA OSCAR;;DUPREE TOM;;SCHOFIELD KAREN;;STEWART ALAN;;SWAIN SIMON;;WITHALL DAVID,BARBA OSCAR;;DUPREE TOM;;SCHOFIELD KAREN;;STEWART ALAN;;SWAIN SIMON;;WITHALL DAVID,,https://lens.org/159-225-211-290-591,Patent Application,yes,36,4,2,2,0,A61K31/454;;A61K31/4545;;A61K31/506;;A61P3/10;;C07D401/12;;C07D401/14;;C07D413/14,A61K31/454;;A61K31/4545;;A61K31/506;;A61P3/10,,7,6,055-758-275-430-910;;165-864-846-333-813;;130-574-196-490-482;;055-758-275-430-910;;048-496-509-447-555;;020-034-478-792-563,10.1016/j.bmcl.2007.10.063;;17977724;;10.1002/chin.200552163;;10.1016/j.bmcl.2005.03.077;;15863294;;10.1016/j.bmcl.2007.10.063;;17977724;;10.1016/s0040-4020(99)00683-3;;2535825;;10.2337/diabetes.38.1.44;;10.2337/diab.38.1.44,"CORBETT ET AL: ""Design and synthesis of potent amido- and benzyl-substituted cis-3-amino-4-(2-cyanopyrrolidide)pyrrolidinyl DPP-IV inhibitors"", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 17, no. 24, 22 October 2007 (2007-10-22), pages 6707 - 6713, XP022339559, ISSN: 0960-894X, DOI: DOI:10.1016/J.BMCL.2007.10.063;;ZHAO, BIOORG. MED. CHEM. LETT., vol. 15, 2005, pages 3992 - 3995;;FUMIHIKO, BIOORG. MED. CHEM. LETT, vol. 15, 2005, pages 2441 - 2445;;CORBETT, BIOORG. MED. CHEM. LETT, vol. 17, 2007, pages 6707 - 6713;;T.W. GREENE, P.G.M. WUTS: ""Protective Groups in Organic Chemistry"", 1991, WILEY-INTERSCIENCE;;TETRAHEDRON, vol. 55, 1999, pages 11619 - 11639;;ZHANG HJ, WALSETH TF, ROBERTSON RP: ""Insulin secretion and cAMP metabolism in HIT cells. Reciprocal and serial passage-dependent relationships"", DIABETES, vol. 38, no. 1, January 1989 (1989-01-01), pages 44 - 8",PENDING
30,EP,A1,EP 2535711 A1,157-178-875-977-423,2012-12-19,2012,EP 11382199 A,2011-06-15,EP 11382199 A,2011-06-15,Diagnostic marker for acute coronary syndrome,The invention discloses an  in vitro  method for diagnosing acute coronary syndrome in a patient. The method is performed in blood and uses means to detect selective compounds.,FUNDACIO INST DE RECERCA HOSPITAL UNI VALL D HEBRON FUNDACIO PRIVADA;;ENTE PUBLICO HOSPITAL UNIVERSITARIO DE FUENLABRADA,CARCIA DORADO DAVID;;BARBA VERT IGNASI;;ALONSO MARTIN JOAQUIN JESUS;;CRISTOBAL VARELA CARMEN,,https://lens.org/157-178-875-977-423,Patent Application,yes,1,0,2,2,0,G01N33/6893;;G01N2800/324,G01N33/50,,9,8,104-123-973-342-674;;032-019-112-690-781;;087-490-293-113-157;;032-019-112-690-781;;028-685-958-523-899;;085-654-792-765-593;;026-959-919-392-833;;028-685-958-523-899,10.1016/j.jacc.2009.09.071;;20359589;;20372757;;20439123;;10.1016/j.ijcard.2010.04.016;;20372757;;10.1038/nm802;;12447357;;10.1038/nm1202-802;;10.1038/nm1432;;16732278;;18581408;;10.1002/mrm.21632;;10.1038/nm802;;12447357;;10.1038/nm1202-802,"SCIRICA B M: ""Acute Coronary Syndrome. Emerging Tools for Diagnosis and Risk Assessment"", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 20100406 ELSEVIER USA USA LNKD- DOI:10.1016/J.JACC.2009.09.071, vol. 55, no. 14, 6 April 2010 (2010-04-06), pages 1403 - 1415, XP002656644, ISSN: 0735-1097;;MOE KYAW THU ET AL: ""Current trends in diagnostic biomarkers of acute coronary syndrome"", ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE, ACADEMY OF MEDICINE, SG, vol. 39, no. 3, 1 March 2010 (2010-03-01), pages 210 - 215, XP009151183, ISSN: 0304-4602;;FERNÁNDEZ-BERGÉS D ET AL: ""Clinical scores and patient risk stratification in non-ST elevation acute coronary syndrome"", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 146, no. 2, 21 January 2011 (2011-01-21), pages 219 - 224, XP009151182, ISSN: 0167-5273, [retrieved on 20100502], DOI: 10.1016/J.IJCARD.2010.04.016;;MOE ET AL.: ""Current Trends in Diagnostic Biomarkers of Acute Coronary Syndrome"", ANNALS ACADEMY MEDICINE SINQAPORE, vol. 39, 2010, pages 210 - 215, XP009151183;;BRINDLE ET AL.: ""Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NNMR-based metabonomics"", NATURE MEDICINE, vol. 8, no. 12, 2002, pages 1439 - 1444;;KIRSCHENLOHR ET AL.: ""Proton NMR analysis of plasma is a weak predictor of coronary artery disease"", NATURE MEDICINE, vol. 12, no. 6, 2006, pages 705 - 709, XP055021934, DOI: doi:10.1038/nm1432;;BARBA ET AL.: ""Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease"", MAQN. RESON. MED., vol. 60, 2008, pages 27 - 32;;BRINDLE ET AL.: ""Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-NMR-based metabonomics"", NATURE MEDICINE, vol. 8, no. 12, 2002, pages 1439 - 1444, XP002975960, DOI: doi:10.1038/nm802;;BARBA ET AL.: ""Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease"", MAQN RESON MED., vol. 60, 2008, pages 27 - 32",DISCONTINUED
31,WO,A1,WO 2012/172013 A1,005-035-812-067-430,2012-12-20,2012,EP 2012061344 W,2012-06-14,EP 11382199 A,2011-06-15,DIAGNOSTIC MARKER FOR ACUTE CORONARY SYNDROME,The invention discloses an in vitro method for diagnosing acute coronary syndrome in a patient. The method is performed in blood and uses means to detect selective compounds.,FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA;;ENTE PUBLICO HOSPITAL UNIVERSITARIO DE FUENLABRADA;;GARCIA DORADO DAVID;;BARBA VERT IGNASI;;ALONSO MARTIN JOAQUIN JESUS;;CRISTOBAL VARELA CARMEN,GARCIA DORADO DAVID;;BARBA VERT IGNASI;;ALONSO MARTIN JOAQUIN JESUS;;CRISTOBAL VARELA CARMEN,,https://lens.org/005-035-812-067-430,Patent Application,yes,1,0,2,2,0,G01N33/6893;;G01N2800/324,G01N33/50,,9,9,104-123-973-342-674;;032-019-112-690-781;;087-490-293-113-157;;032-019-112-690-781;;028-685-958-523-899;;085-654-792-765-593;;026-959-919-392-833;;028-685-958-523-899;;026-959-919-392-833,10.1016/j.jacc.2009.09.071;;20359589;;20372757;;20439123;;10.1016/j.ijcard.2010.04.016;;20372757;;10.1038/nm802;;12447357;;10.1038/nm1202-802;;10.1038/nm1432;;16732278;;18581408;;10.1002/mrm.21632;;10.1038/nm802;;12447357;;10.1038/nm1202-802;;18581408;;10.1002/mrm.21632,"SCIRICA B M: ""Acute Coronary Syndrome. Emerging Tools for Diagnosis and Risk Assessment"", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY 20100406 ELSEVIER USA USA LNKD- DOI:10.1016/J.JACC.2009.09.071, vol. 55, no. 14, 6 April 2010 (2010-04-06), pages 1403 - 1415, XP002656644, ISSN: 0735-1097;;MOE KYAW THU ET AL: ""Current trends in diagnostic biomarkers of acute coronary syndrome"", ANNALS OF THE ACADEMY OF MEDICINE, SINGAPORE, ACADEMY OF MEDICINE, SG, vol. 39, no. 3, 1 March 2010 (2010-03-01), pages 210 - 215, XP009151183, ISSN: 0304-4602;;FERNÁNDEZ-BERGÉS D ET AL: ""Clinical scores and patient risk stratification in non-ST elevation acute coronary syndrome"", INTERNATIONAL JOURNAL OF CARDIOLOGY, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 146, no. 2, 21 January 2011 (2011-01-21), pages 219 - 224, XP009151182, ISSN: 0167-5273, [retrieved on 20100502], DOI: 10.1016/J.IJCARD.2010.04.016;;MOE ET AL.: ""Current Trends in Diagnostic Biomarkers of Acute Coronary Syndrome"", ANNALS ACADEMY MEDICINE SINQAPORE, vol. 39, 2010, pages 210 - 215, XP009151183;;BRINDLE ET AL.: ""Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NNMR-based metabonomics"", NATURE MEDICINE, vol. 8, no. 12, 2002, pages 1439 - 1444;;KIRSCHENLOHR ET AL.: ""Proton NMR analysis of plasma is a weak predictor of coronary artery disease"", NATURE MEDICINE, vol. 12, no. 6, 2006, pages 705 - 709, XP055021934, DOI: doi:10.1038/nm1432;;BARBA ET AL.: ""Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease"", MAQN. RESON. MED., vol. 60, 2008, pages 27 - 32;;BRINDLE ET AL.: ""Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using H-NMR-based metabonomics"", NATURE MEDICINE, vol. 8, no. 12, 2002, pages 1439 - 1444, XP002975960, DOI: doi:10.1038/nm802;;BARBA ET AL.: ""Nuclear magnetic resonance-based metabolomics predicts exercise-induced ischemia in patients with suspected coronary artery disease"", MAGN RESON MED., vol. 60, 2008, pages 27 - 32",PENDING
32,US,A1,US 2005/0195545 A1,122-453-704-220-729,2005-09-08,2005,US 4927805 A,2005-02-01,US 4927805 A;;US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Method of detecting run-dry conditions in fuel systems,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line, such as current levels in a three-phase power line, and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",MLADENIK JOHN E.;;EVANS DAVID L.;;BARBA JOSE M.;;FISH DANIEL E.;;BENCH GERALD;;WAGNER ANDREW,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;FISH DANIEL E;;BENCH GERALD;;WAGNER ANDREW,TDG AEROSPACE INC (2005-04-25),https://lens.org/122-453-704-220-729,Patent Application,yes,8,43,2,8,0,H02H3/00;;H02H3/00,H02H3/00;;H02H3/08,361/93.1,0,0,,,,ACTIVE
33,US,B2,US 7352550 B2,053-140-801-364-160,2008-04-01,2008,US 4927805 A,2005-02-01,US 4927805 A;;US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Method of detecting run-dry conditions in fuel systems,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line, such as current levels in a three-phase power line, and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",TDG AEROSPACE INC,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;FISH DANIEL E;;BENCH GERALD;;WAGNER ANDREW,TDG AEROSPACE INC (2005-04-25),https://lens.org/053-140-801-364-160,Granted Patent,yes,8,35,2,8,0,H02H3/00;;H02H3/00,H02H7/00;;H02H3/00;;H02H3/08,361/87;;361/62,0,0,,,,ACTIVE
34,US,A1,US 2006/0072270 A1,069-324-148-756-280,2006-04-06,2006,US 4864505 A,2005-01-31,US 4864505 A;;US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Fuel system safety device for run-dry conditions,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line, such as current levels in a three-phase power line, and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;FISH DANIEL E;;BENCH GERALD;;WAGNER ANDREW,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;FISH DANIEL E;;BENCH GERALD;;WAGNER ANDREW,TDG AEROSPACE INC (2004-05-04),https://lens.org/069-324-148-756-280,Patent Application,yes,6,16,2,8,0,H01H2071/006;;H02H3/00;;H02H3/042;;H02H3/00;;H01H2071/006;;H02H3/042,H02H9/02;;H02H3/00;;H02H3/08,361/93.1,0,0,,,,INACTIVE
35,US,B2,US 7342763 B2,016-666-030-665-33X,2008-03-11,2008,US 4864505 A,2005-01-31,US 4864505 A;;US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Fuel system safety device for run-dry conditions,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line, such as current levels in a three-phase power line, and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",TDG AEROSPACE INC,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;FISH DANIEL E;;BENCH GERALD;;WAGNER ANDREW,TDG AEROSPACE INC (2004-05-04),https://lens.org/016-666-030-665-33X,Granted Patent,yes,6,24,2,8,0,H01H2071/006;;H02H3/00;;H02H3/042;;H02H3/00;;H01H2071/006;;H02H3/042,H02H3/00;;H02H7/00;;H02H3/08,361/119;;361/93.1,0,0,,,,INACTIVE
36,US,B2,US 7466146 B2,169-852-287-021-940,2008-12-16,2008,US 37307106 A,2006-03-10,US 37307106 A,2006-03-10,Frozen material detection using electric field sensor,"An electric field sensor may be used to detect accumulation of frozen material. In one embodiment, an e-field system includes a first electrode, a second electrode located at a distance from the first electrode, the second electrode forming a capacitive element with the first electrode, wherein a gap is present between the first and second electrodes, and an electric field sensor having an electrode terminal coupled to the first electrode and providing an electric field output value representative of an amount of frozen material located in the gap between the first and second electrodes. The system may also include a first insulator adjacent the first electrode and outside the gap, and a conductive layer adjacent the first insulator, where the first insulator is between the first electrode and the conductive layer, and where a shield output of the electric field sensor is coupled to the conductive layer.",FREESCALE SEMICONDUCTOR INC,STEWART BRADLEY CLAYTON;;DE ALBA GARCIN SERGIO GARCIA;;GARCIA ROGELIO REYNA;;BARBA GABRIEL SANCHEZ;;WILSON DAVID L,NXP USA INC (2006-03-07),https://lens.org/169-852-287-021-940,Granted Patent,yes,16,21,2,2,0,G01N27/22;;G01N27/22,G01R27/26;;F25D21/02;;G01R29/12;;G08B19/02;;G08B21/00,324/663;;324/671;;324/686;;324/688;;324/457;;62/128;;340/580;;340/962,3,0,,,"Freescale Semiconductor Technical Data; ""Electric Field Imaging Device""; Apr. 2005; 22 pp.; Freescale Semiconductor, Inc. http://www.freescale.com/files/analog/doc/data-sheet/MC33794.pdf.;;Stewart, Brad; ""Beyond Touch Panels: Appliance Solutions Using Electric Field Sensors""; 56th Annual International Appliance Technical Conference and Exhibition; Mar. 28-30, 2005; 10 pg article & pp. 1 & 4 of Conference Schedule; Rosemont, IL.;;Motorola Semiconductor Products Sector; ""Maximizing Cost Effectiveness""; Mar. 2004; Accompanying Declaration.",INACTIVE
37,WO,A3,WO 2004/114492 A3,113-069-465-464-503,2005-04-21,2005,US 2004/0019061 W,2004-06-12,US 47859903 P;;US 54709904 P,2003-06-13,SYSTEMS AND METHODS FOR FAULT-BASED POWER SIGNAL INTERRUPTION,"Systems, methods, and apparatus (100) for fault detection and interruption in power lines are provided. Circuitry (110) is implemented via software and hardware that is configured to sense an operational aspect of a power line and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry (110) can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",TDG AEROSPACE INC;;MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,,https://lens.org/113-069-465-464-503,Search Report,yes,1,0,4,8,0,H02H3/00;;H02H3/00;;H01H2071/006;;H01H2071/006;;H02H3/04;;H02H3/042;;H02H3/042,H02H3/00;;H02H3/04;;H02H3/08,,0,0,,,,PENDING
38,WO,A2,WO 2004/114492 A2,104-231-095-061-091,2004-12-29,2004,US 2004/0019061 W,2004-06-12,US 47859903 P;;US 54709904 P,2003-06-13,SYSTEMS AND METHODS FOR FAULT-BASED POWER SIGNAL INTERRUPTION,"Systems, methods, and apparatus (100) for fault detection and interruption in power lines are provided. Circuitry (110) is implemented via software and hardware that is configured to sense an operational aspect of a power line and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry (110) can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time).",TDG AEROSPACE INC;;MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,,https://lens.org/104-231-095-061-091,Patent Application,yes,0,8,4,8,0,H02H3/00;;H02H3/00;;H01H2071/006;;H01H2071/006;;H02H3/04;;H02H3/042;;H02H3/042,H02H3/00;;H02H3/04;;H02H3/08,,0,0,,,,PENDING
39,US,A1,US 2007/0209446 A1,103-437-422-437-218,2007-09-13,2007,US 37307106 A,2006-03-10,US 37307106 A,2006-03-10,Frozen material detection using electric field sensor,"An electric field sensor may be used to detect accumulation of frozen material. In one embodiment, an e-field system includes a first electrode, a second electrode located at a distance from the first electrode, the second electrode forming a capacitive element with the first electrode, wherein a gap is present between the first and second electrodes, and an electric field sensor having an electrode terminal coupled to the first electrode and providing an electric field output value representative of an amount of frozen material located in the gap between the first and second electrodes. The system may also include a first insulator adjacent the first electrode and outside the gap, and a conductive layer adjacent the first insulator, where the first insulator is between the first electrode and the conductive layer, and where a shield output of the electric field sensor is coupled to the conductive layer.",STEWART BRADLEY C;;DE ALBA GARCIN SERGIO G;;GARCIA ROGELIO R;;BARBA GABRIEL S;;WILSON DAVID L,STEWART BRADLEY C;;DE ALBA GARCIN SERGIO G;;GARCIA ROGELIO R;;BARBA GABRIEL S;;WILSON DAVID L,NXP USA INC (2006-03-07),https://lens.org/103-437-422-437-218,Patent Application,yes,16,8,2,2,0,G01N27/22;;G01N27/22,G01B7/16,73/780,0,0,,,,INACTIVE
40,US,B2,US 7254004 B2,082-988-070-570-699,2007-08-07,2007,US 86623604 A,2004-06-12,US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Systems and methods for fault-based power signal interruption,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time). The types of faults can include transient type faults that can include ground, arc, line-to-line, and imbalance type faults and can also include steady state type faults (e.g., those showing wear in the machinery of a load).",TDG AEROSPACE INC,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,TDG AEROSPACE (2004-06-10),https://lens.org/082-988-070-570-699,Granted Patent,yes,7,39,4,8,0,H02H3/00;;H02H3/00;;H01H2071/006;;H01H2071/006;;H02H3/04;;H02H3/042;;H02H3/042,H02H3/00;;H02H3/04;;H02H3/08,361/93.1,0,0,,,,INACTIVE
41,US,A1,US 2005/0018371 A1,181-050-226-444-202,2005-01-27,2005,US 86623604 A,2004-06-12,US 86623604 A;;US 47859903 P;;US 54709904 P,2003-06-13,Systems and methods for fault-based power signal interruption,"Systems, methods, and apparatus for fault detection and interruption in power lines are provided. Circuitry is implemented via software and hardware that is configured to sense an operational aspect of a power line and apply signal processing to the sensed operational aspect to detect faults including different types of faults such as transient and steady state faults and can also be configured to identify the type of fault. Information on the fault and the identification of the type of fault can be displayed, stored, or some other output operation can be implemented. Circuitry can be implemented to provide digital signal processing and analog signal processing to, for example, independently and in parallel (e.g., redundant operation) detect faults and respond to faults as they occur (i.e., in real time). The types of faults can include transient type faults that can include ground, arc, line-to-line, and imbalance type faults and can also include steady state type faults (e.g., those showing wear in the machinery of a load).",MLADENIK JOHN E.;;EVANS DAVID L.;;BARBA JOSE M.;;LARSON WAYNE L.;;FISH DANIEL E.;;BENCH GERALD,MLADENIK JOHN E;;EVANS DAVID L;;BARBA JOSE M;;LARSON WAYNE L;;FISH DANIEL E;;BENCH GERALD,TDG AEROSPACE (2004-06-10),https://lens.org/181-050-226-444-202,Patent Application,yes,7,77,4,8,0,H02H3/00;;H02H3/00;;H01H2071/006;;H01H2071/006;;H02H3/04;;H02H3/042;;H02H3/042,H02H3/00;;H02H3/04;;H02H3/08,361/78,0,0,,,,INACTIVE
42,CN,A,CN 116734848 A,197-245-004-168-864,2023-09-12,2023,CN 202310036353 A,2020-12-31,US 202062957524 P;;CN 202080098009 A;;US 2020/0067756 W,2020-01-06,Vehicle navigation with respect to pedestrians and determination of vehicle free space,"Systems and methods are provided for vehicle navigation. In one implementation, a navigation system for a host vehicle may include at least one processor programmed to: receive, from a camera onboard the host vehicle, at least one captured image representing an environment of the vehicle; detecting a pedestrian represented in the at least one captured image; analyzing the at least one captured image to determine an angular rotation indicator and a tilt angle indicator associated with the head of the pedestrian represented in the at least one captured image; and causing at least one navigation action of the primary vehicle based on the angular rotation indicator and the tilt angle indicator associated with the head of the pedestrian.",MOBILEYE VISION TECHNOLOGIES LTD,BENTOLILA JAKOB;;GEILER IDAN;;REGEV LEO;;BARBA TOMMER;;BENOU ARIEL;;ALONI DAVID;;KURZNER DMITRY;;CARIOU JACK;;BUEKER HANNAEL,,https://lens.org/197-245-004-168-864,Patent Application,no,0,0,2,14,0,G01C21/20;;G01C21/3602,G01C21/20;;G01C21/36,,0,0,,,,PENDING
43,ES,B1,ES 2375026 B1,125-729-439-108-894,2013-03-20,2013,ES 200803715 A,2008-12-26,ES 200803715 A,2008-12-26,MODULO Y METODOS PARA LA INTERCONEXION DE EQUIPOS HETEROGENEOS CON RECURSOS LIMITADOS POR MEDIO DE MIDDLEWARES DE COMUNICACIONES ORIENTADOS A OBJETO.,,UNIV CASTILLA LA MANCHA,VILLA ALISES DAVID;;MOYA FERNANDEZ FRANCISCO;;VILLANUEVA MOLINA FELIX JESUS;;BARBA ROMERO JESUS;;RINCON CALLE FERNANDO;;LOPEZ LOPEZ JUAN CARLOS,,https://lens.org/125-729-439-108-894,Granted Patent,no,0,1,4,4,0,G06F9/54;;G06F9/54;;G06F9/465;;G06F9/541,G06F9/54;;H04Q9/00,,0,0,,,,ACTIVE
44,ES,B1,ES 2353792 B1,173-986-591-956-095,2012-01-30,2012,ES 200900148 A,2009-01-20,ES 200900148 A,2009-01-20,METODO Y SISTEMA PARA LA COMUNICACION INDIRECTA DE LOS COMPONENTES DE UN SISTEMA ELECTRONICO.,,UNIV CASTILLA LA MANCHA,LOPEZ LOPEZ JUAN CARLOS;;RINCON CALLE FERNANDO;;MOYA FERNANDEZ FRANCISCO;;BARBA ROMERO JESUS;;VILLA ALISES DAVID;;VILLANUEVA MOLINA FELIX JESUS,,https://lens.org/173-986-591-956-095,Granted Patent,no,0,0,2,2,0,G06F13/38,G06F13/38,,0,0,,,,ACTIVE
45,ES,A1,ES 2353792 A1,098-276-235-762-695,2011-03-04,2011,ES 200900148 A,2009-01-20,ES 200900148 A,2009-01-20,"Method and system for the indirect communication of the components of an electronic system. (Machine-translation by Google Translate, not legally binding)","Method and system for the indirect communication of the components of an electronic system. The invention relates to a new method and communication system, called indirect communication, between the components or hardware devices of an electronic system. It is part of the field of so-called chip systems, which integrate the different traditional components of a computer into silicon chips, such as processor, memory, peripheral controllers, etc. It focuses on the resolution of the problems associated with the physical dependence of the existing addressing modes through a hardware infrastructure. Unlike other implementations that use software to (re) configure the physical addresses by means of scripts in the devices, the logic necessary to obtain the physical address of the device with which it wants to communicate at runtime. By delegating to the devices the responsibility to update their references, the infrastructure necessary for software execution can be simplified or even eliminated in some applications, reducing development times and system complexity. (Machine-translation by Google Translate, not legally binding)",UNIV CASTILLA LA MANCHA,RINCON CALLE FERNANDO;;LOPEZ LOPEZ JUAN CARLOS;;VILLA ALISES DAVID;;BARBA ROMERO JESUS;;MOYA FERNANDEZ FRANCISCO;;VILLANUEVA MOLINA FELIX JESUS,,https://lens.org/098-276-235-762-695,Patent Application,no,3,0,2,2,0,G06F13/38,G06F13/38,,0,0,,,,ACTIVE
46,ES,A1,ES 2375026 A1,021-904-369-196-001,2012-02-24,2012,ES 200803715 A,2008-12-26,ES 200803715 A,2008-12-26,Module and methods for the interconnection of heterogeneous equipment with limited resources by means of object-oriented communication middleware,"The invention relates to a module and methods for the integration of distributed objects in embedded systems which can be implemented by means of two complementary alternatives: embedded software and hardware synthesis. The method allows manufacturing less expensive and smaller remote sensing and actuation devices, furthermore maintaining a very high degree of interoperability with the communication middleware, which considerably facilitates their operation possibilities and their integration with other pre-existing systems.",UNIV CASTILLA LA MANCHA,VILLA ALISES DAVID;;MOYA FERNANDEZ FRANCISCO;;VILLANUEVA MOLINA FELIX JESUS;;BARBA ROMERO JESUS;;RINCON CALLE FERNANDO;;LOPEZ LOPEZ JUAN CARLOS,,https://lens.org/021-904-369-196-001,Patent Application,no,0,0,4,4,0,G06F9/54;;G06F9/54;;G06F9/465;;G06F9/541,G06F9/54;;H04Q9/00,,3,3,087-301-390-857-371;;044-385-039-039-428;;141-320-422-160-342,10.1002/wcm.545;;10.1109/date.2007.364431;;10.1109/isse.2004.1490370,"F. Moya, D. Villa, F. J. Villanueva, J. Barba, F. Rincón, J. C. López ""Embedding standard distributed object-oriented middlewares in wireless sensor networks"" 28-08-2007. Documento recuperado de Internet. Dirección web: https://arco.esi.uclm.es/public/papers/2009-WCMC.pdf;;Villanueva F J; Villa D; Moya F; Barba J; Rincon F; Lopez J C. ""Leightweight Middleware for Seamless HW-SW Interoperability, with Application to Wireless Sensor Networks"" Design, Automation&Test in Europe Conference&Exhibition, 2007. DATE '07.01-04-2007, Págs: 1 - 6, ISBN 978-3-9810801-2-4 ; ISBN 3-9810801-2-2, doi:10.1109/DATE.2007.364431;;Drumea A; Popescu C ""Finite state machines and their applications in software for industrial control "" Electronics Technology: Meeting the Challenges of Electronics Technology Progress, 2004. 27th International Spring Seminar on Bankya, Bulgaria 13-05-2004.Vol. 1, Págs. 25 - 29. ISBN 978-0-7803-8422-4 ; ISBN 0-7803-8422-9.",ACTIVE
47,US,A1,US 2022/0114472 A1,126-458-893-122-877,2022-04-14,2022,US 202017066279 A,2020-10-08,US 202017066279 A,2020-10-08,SYSTEMS AND METHODS FOR GENERATING MACHINE LEARNING-DRIVEN TELECAST FORECASTS,Systems and methods for generating telecast forecasts is provided. An automated forecasting system uses machine learning-driven a forecast model for generating forecast for various telecasts varying periods of time. Estimate values that are used to generate the forecasts may be determined based on deriving trends and correlations from telecasts data using machine learning. The forecasting system may compare estimate values and actual values associated with the various telecasts and subsequently update the forecast model based on the comparison. The forecast model may be displayed on an electronic device of a client electronic device and may be updated or influenced by telecast providers.,NBCUNIVERSAL MEDIA LLC,DAVIES CAMERON;;MORALES BARBA MARCO ANTONIO;;SYNDER DAVID L;;JIAN TONG;;CHEN JIABIN;;DEB SOUDEEP;;ESSUMAN NANA YAW;;WANG JIACHENG,NBCUNIVERSAL MEDIA LLC (2020-09-11),https://lens.org/126-458-893-122-877,Patent Application,yes,14,1,1,1,0,G01W1/10;;G06N20/00;;G06N7/01;;G06F18/24;;G06N20/00;;G01W1/10;;H04N21/251,G06N20/00;;G01W1/10;;G06K9/62,,0,0,,,,PENDING
48,EP,A1,EP 2948551 A1,097-422-675-609-156,2015-12-02,2015,EP 14706098 A,2014-01-23,EP 13305082 A;;IB 2014058500 W;;EP 14706098 A,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,,PIERRE FABRE MÉDICAMENT S A S;;FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/097-422-675-609-156,Patent Application,yes,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,ACTIVE
49,US,A1,US 2015/0352055 A1,005-823-212-810-523,2015-12-10,2015,US 201414763181 A,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORAD GARCIA ANTONIO DAVID,PIERRE FABRE MEDICAMENT S.A.S (2015-10-22);;FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA (2015-10-22),https://lens.org/005-823-212-810-523,Patent Application,yes,1,3,21,21,60,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K9/50,,1,1,035-428-461-300-004,9713978;;10.3109/10611869808995882,"Lewis et al. (Jour. Drug Target. (1998) vol. 5, pages 291-302).",DISCONTINUED
50,ZA,B,ZA 201505602 B,063-359-062-781-866,2017-05-31,2017,ZA 201505602 A,2015-08-04,EP 13305082 A;;IB 2014058500 W,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,,FUNDACIO HOSPITAL UNIV VALL D'HEBRON - INSTITUT DE RECERCA;;PIERRE FABRE MEDICAMENT S A S,ANTONIO DAVID GARCIA-DORADO GARCIA;;IGNASI BARBA VERT;;ANTONIO RODRIGUEZ SINOVAS;;NEUS BELLERA GOTARDA;;AMADEO PEREZ;;EULALIA FERRET;;MIGUEL-ANGEL ASIN,,https://lens.org/063-359-062-781-866,Granted Patent,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,,,0,0,,,,ACTIVE
51,ES,T3,ES 2688160 T3,062-489-832-619-953,2018-10-31,2018,ES 14706098 T,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,Composición que comprende un antagomir encapsulado,"Composición que comprende una cantidad eficaz de al menos un inhibidor de un miARN involucrado en la angiogénesis y presentación de una actividad antiangiogénica, o su precursor; en el que dicho inhibidor es un oligonucleótido antisentido que es complementario a dicho miARN, o su precursor, y se microencapsula en microesferas poliméricas biodegradables y biocompatibles, en la que dichas microesferas están hechas de un copolímero seleccionado de entre poli-d,l-lactida (PLA) y poli-d,l-lactida-co-glicolida (PLGA), combinándose dicho polímero opcionalmente con uno o varios de otros polímeros.",PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNIV VALL D HEBRON INSTITUT DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/062-489-832-619-953,Granted Patent,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,ACTIVE
52,AU,A1,AU 2014/208419 A1,087-307-387-997-055,2015-08-13,2015,AU 2014/208419 A,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,Composition comprising an encapsulated antagomir,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA;;PIERRE FABRE MEDICAMENT S A S,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/087-307-387-997-055,Patent Application,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,DISCONTINUED
53,MX,A,MX 2015009323 A,125-013-754-752-061,2016-04-04,2016,MX 2015009323 A,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR.,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MEDICAMENT S A S,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;SINOVAS ANTONIO RODRIGUEZ;;VERT IGNASI BARBA;;GARCIA ANTONIO DAVID GARCIA-DORADO,,https://lens.org/125-013-754-752-061,Patent Application,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,PENDING
54,CA,A1,CA 2898958 A1,100-014-031-269-372,2014-07-31,2014,CA 2898958 A,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/100-014-031-269-372,Patent Application,no,0,0,21,21,60,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,DISCONTINUED
55,BR,A2,BR 112015017650 A2,138-433-680-098-783,2017-11-21,2017,BR 112015017650 A,2014-01-23,IB 2014058500 W;;EP 13305082 A,2013-01-24,composição compreendendo um antagomir encapsulado,"1/1 resumo composição compreendendo um antagomir encapsulado a invenção diz respeito a uma composição compreendendo uma quantidade eficaz de pelo menos um inibidor de um mirna envolvido na angiogênese, ou um precursor do mesmo, em que o dito inibidor é microencapsulado dentro de microesferas poliméricas biodegradáveis e biocompatíveis. a invenção também diz respeito ao uso da dita composição para prevenir ou tratar distúrbios cardíacos, incluindo distúrbios cardíacos causados pela isquemia.",FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA;;PIERRE FABRE MEDICAMENT S A S,AMADEO PEREZ;;ANTONIO DAVID GARCIA-DORADO GARCIA;;ANTONIO RODRIGUEZ SINOVAS;;EULALIA FERRET;;IGNASI BARBA VERT;;MIGUEL-ANGEL ASIN;;NEUS BELLERA GOTARDA,,https://lens.org/138-433-680-098-783,Patent Application,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,A61K31/712;;C12N15/113,,0,0,,,,DISCONTINUED
56,ES,T3,ES 2606636 T3,105-379-224-448-223,2017-03-24,2017,ES 13305082 T,2013-01-24,EP 13305082 A,2013-01-24,Composición que comprende un antagomir encapsulado,"Composición que comprende una cantidad efectiva de por lo menos un inhibidor de un miARN involucrado en la angiogénesis, en la que tal inhibidor se microencapsula en microesferas biodegradables y biocompatibles poliméricas, en la que por lo menos 50% de dichas microesferas presentan un diámetro comprendido entre 5 y 15 μm, y en la que el dicho por lo menos un inhibidor consiste en un oligonucleótido antisentido dirigido a o que es complementario a miR-92a.",PIERRE FABRE MÉDICAMENT S A S;;FUNDACIÓ HOSPITAL UNIV VALL D' HEBRON - INSTITUT DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GARCIA-DORADO GARCIA ANTONIO DAVID;;VERT IGNASI BARBA;;RODRIGUEZ SINOVAS ANTONIO;;GOTARDA NEUS BELLERA,,https://lens.org/105-379-224-448-223,Granted Patent,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,ACTIVE
57,CN,A,CN 105229151 A,164-544-305-635-983,2016-01-06,2016,CN 201480017728 A,2014-01-23,IB 2014058500 W;;EP 13305082 A,2013-01-24,Composition comprising an encapsulated antagomir,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/164-544-305-635-983,Patent Application,no,0,3,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,5,3,016-991-995-988-53X;;076-907-022-080-068;;064-416-375-486-707,12628320;;10.1016/s0169-409x(02)00228-4;;19460962;;10.1126/science.1174381;;19545221;;10.3109/02652040902954729,"FUJITA，ET AL: ""Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin α5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium"", 《CIRCULATION》;;JAYANTH ET AL: ""B iodegradable nanoparticles for drug and gene delivery to cells and tissue"", 《ELSEVIER SCIENCE 》;;BONAUER ET AL: ""MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice"", 《SCIENCE》;;ANGELO ET AL: ""Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles"", 《J MICROENCAPSUL》;;DEEPAK等: ""《纳米粒药物输送系统》"", 30 September 2010, 北京大学医学出版社",DISCONTINUED
58,EP,A1,EP 2759595 A1,158-662-386-120-841,2014-07-30,2014,EP 13305082 A,2013-01-24,EP 13305082 A,2013-01-24,Composition comprising an encapsulated antagomir,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MÉDICAMENT S A S;;FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GARCIA-DORADO GARCIA ANTONIO DAVID;;VERT IGNASI BARBA;;RODRIGUEZ SINOVAS ANTONIO;;GOTARDA NEUS BELLERA,,https://lens.org/158-662-386-120-841,Patent Application,yes,0,2,21,21,60,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,3,3,076-907-022-080-068;;064-416-375-486-707;;016-991-995-988-53X,19460962;;10.1126/science.1174381;;19545221;;10.3109/02652040902954729;;12628320;;10.1016/s0169-409x(02)00228-4,"BONAUER ANGELIKA ET AL: ""MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 324, no. 5935, 26 June 2009 (2009-06-26), pages 1710 - 1713, XP002575234, ISSN: 0036-8075;;D'ANGELO IVANA ET AL: ""Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles."", JOURNAL OF MICROENCAPSULATION 2010, vol. 27, no. 1, 2010, pages 57 - 66, XP002700281, ISSN: 1464-5246;;PANYAM J ET AL: ""Biodegradable nanoparticles for drug and gene delivery to cells and tissue"", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 55, no. 3, 24 February 2003 (2003-02-24), pages 329 - 347, XP008096954, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00228-4",ACTIVE
59,KR,A,KR 20160018451 A,145-625-105-544-37X,2016-02-17,2016,KR 20157022914 A,2014-01-23,EP 13305082 A;;IB 2014058500 W,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,"본 발명은 혈관생성에 관련된 적어도 하나의 miRNA, 또는 이의 전구체의 억제자의 유효량을 포함하는 조성물에 관한 것이며, 상기 억제자는 폴리머 생분해성 및 생체적합성 마이크로스피어로 미세 캡슐화된다. 또한 본 발명은 국소 빈혈(ischemy)에 의해 유발되는 심장 질환을 포함하는 심장 질환을 예방 또는 치료하기 위한 상기 조성물의 용도와 관련된다.",PIERRE FABRE MEDICAMENT SA;;FUNDACIO PRIVADA INST DE RECERCA HOSPITAL UNI VALL HEBRON,ASIN MIGUEL ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA DORADO GARCIA ANTONIO DAVID,,https://lens.org/145-625-105-544-37X,Patent Application,no,0,0,21,21,120,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,A61K31/712;;C12N15/113,,0,0,,,,DISCONTINUED
60,EP,B1,EP 2948551 B1,001-569-840-046-558,2018-05-02,2018,EP 14706098 A,2014-01-23,EP 13305082 A;;IB 2014058500 W;;EP 14706098 A,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,,PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNIV VALL DHEBRON INSTITUT DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/001-569-840-046-558,Granted Patent,yes,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,7,0,,,"DATABASE BIOSIS [Online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2011 (2011-11), FUJITA MASANORI ET AL: ""Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin a5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium"", XP055116076, Database accession no. PREV201200224175 & CIRCULATION, vol. 124, no. 21, Suppl. S, November 2011 (2011-11), page A12590, SCIENTIFIC SESSIONS OF THE AMERICAN-HEART-ASSOCIATION/RESUSCITATION SCIENCE SYMPOSIUM; ORLANDO, FL, USA; NOVEMBER 12 -16, 2011 ISSN: 0009-7322(print);;K Ablasser ET AL: ""Cardiovascular biology 1053 P5665 | BENCH Static, but not cyclic tensional forces on the heart increase anti-angiogenic sFlt-1 expression in endothelial cells and inhibit VEGFR-2 activation P5666 | BENCH Intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse"", , 1 August 2013 (2013-08-01), XP055116081, Retrieved from the Internet: URL:http://eurheartj.oxfordjournals.org/co ntent/34/suppl_1/P5666.full.pdf [retrieved on 2014-04-30];;BONAUER ANGELIKA ET AL: ""MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 324, no. 5935, 26 June 2009 (2009-06-26), pages 1710-1713, XP002575234, ISSN: 0036-8075;;D'ANGELO IVANA ET AL: ""Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles."", JOURNAL OF MICROENCAPSULATION 2010, vol. 27, no. 1, 2010, pages 57-66, XP002700281, ISSN: 1464-5246;;PANYAM J ET AL: ""Biodegradable nanoparticles for drug and gene delivery to cells and tissue"", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 55, no. 3, 24 February 2003 (2003-02-24), pages 329-347, XP008096954, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00228-4;;CLAUDIO IACONETTI ET AL: ""Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury"", BASIC RESEARCH IN CARDIOLOGY, STEINKOPFF-VERLAG, DA, vol. 107, no. 5, 14 August 2012 (2012-08-14), pages 1-14, XP035112376, ISSN: 1435-1803, DOI: 10.1007/S00395-012-0296-Y;;JAGAT R KANWAR ET AL: ""Antiangiogenic therapy using nanotechnological-based delivery system"", DRUG DISCOVERY TODAY, vol. 16, no. 5, 1 March 2011 (2011-03-01), pages 188-202, XP028162998, ISSN: 1359-6446, DOI: 10.1016/J.DRUDIS.2011.01.007 [retrieved on 2011-01-22]",ACTIVE
61,PL,T3,PL 2759595 T3,077-884-498-345-137,2017-09-29,2017,PL 13305082 T,2013-01-24,EP 13305082 A,2013-01-24,Composition comprising an encapsulated antagomir,,PIERRE FABRE MÉDICAMENT S A S;;FUNDACIÓ HOSPITAL UNIV VALL D'HEBRON - INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GARCIA-DORADO GARCIA ANTONIO DAVID;;VERT IGNASI BARBA;;RODRIGUEZ SINOVAS ANTONIO;;GOTARDA NEUS BELLERA,,https://lens.org/077-884-498-345-137,Patent Application,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,0,0,,,,PENDING
62,WO,A1,WO 2014/115103 A1,097-323-326-649-869,2014-07-31,2014,IB 2014058500 W,2014-01-23,EP 13305082 A,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR,"The invention relates to a composition comprising an effective amount of at least one inhibitor of a miRNA involved in the angiogenesis, or a precursor thereof, wherein said inhibitor is microencapsulated into polymeric biodegradable and biocompatible microspheres. The invention also relates to the use of the said composition for preventing or treating cardiac disorders, including cardiac disorders caused by ischemy.",PIERRE FABRE MEDICAMENT S A S;;FUNDACIO HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GOTARDA NEUS BELLERA;;RODRIGUEZ SINOVAS ANTONIO;;VERT IGNASI BARBA;;GARCIA-DORADO GARCIA ANTONIO DAVID,,https://lens.org/097-323-326-649-869,Patent Application,yes,0,4,21,21,60,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,7,6,050-739-581-109-396;;076-907-022-080-068;;064-416-375-486-707;;016-991-995-988-53X;;097-374-489-752-852;;022-494-257-814-183,10.1093/eurheartj/eht310.p5665;;19460962;;10.1126/science.1174381;;19545221;;10.3109/02652040902954729;;12628320;;10.1016/s0169-409x(02)00228-4;;22890560;;10.1007/s00395-012-0296-y;;10.1016/j.drudis.2011.01.007;;21262383,"DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2011 (2011-11-01), FUJITA MASANORI ET AL: ""Inhibition of MicroRNA-92a Enhances Angiogenesis and Cardiomyocyte Regeneration Through Integrin a5-Dependent Accumulation of Stem Cells Into the Infarcted Myocardium"", XP055116076, Database accession no. PREV201200224175;;K ABLASSER ET AL: ""Cardiovascular biology 1053 P5665 | BENCH Static, but not cyclic tensional forces on the heart increase anti-angiogenic sFlt-1 expression in endothelial cells and inhibit VEGFR-2 activation P5666 | BENCH Intracoronary injection of encapsulated antagomir-92a promotes angiogenesis and prevents adverse"", 1 August 2013 (2013-08-01), XP055116081, Retrieved from the Internet <URL:http://eurheartj.oxfordjournals.org/content/34/suppl_1/P5666.full.pdf> [retrieved on 20140430];;BONAUER ANGELIKA ET AL: ""MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 324, no. 5935, 26 June 2009 (2009-06-26), pages 1710 - 1713, XP002575234, ISSN: 0036-8075;;D'ANGELO IVANA ET AL: ""Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles."", JOURNAL OF MICROENCAPSULATION 2010, vol. 27, no. 1, 2010, pages 57 - 66, XP002700281, ISSN: 1464-5246;;PANYAM J ET AL: ""Biodegradable nanoparticles for drug and gene delivery to cells and tissue"", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 55, no. 3, 24 February 2003 (2003-02-24), pages 329 - 347, XP008096954, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00228-4;;CLAUDIO IACONETTI ET AL: ""Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury"", BASIC RESEARCH IN CARDIOLOGY, STEINKOPFF-VERLAG, DA, vol. 107, no. 5, 14 August 2012 (2012-08-14), pages 1 - 14, XP035112376, ISSN: 1435-1803, DOI: 10.1007/S00395-012-0296-Y;;JAGAT R KANWAR ET AL: ""Antiangiogenic therapy using nanotechnological-based delivery system"", DRUG DISCOVERY TODAY, vol. 16, no. 5, 1 March 2011 (2011-03-01), pages 188 - 202, XP028162998, ISSN: 1359-6446, [retrieved on 20110122], DOI: 10.1016/J.DRUDIS.2011.01.007",PENDING
63,HU,T2,HU E032125 T2,034-654-242-470-766,2017-08-28,2017,HU E13305082 A,2013-01-24,EP 13305082 A,2013-01-24,Composition comprising an encapsulated antagomir,,PIERRE FABRE MEDICAMENT S A S;;FUND HOSPITAL UNIV VALL D'HEBRON - INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GARCIA-DORADO GARCIA ANTONIO DAVID;;VERT IGNASI BARBA;;RODRIGUEZ SINOVAS ANTONIO;;GOTARDA NEUS BELLERA,,https://lens.org/034-654-242-470-766,Amended Patent,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,,,0,0,,,,PENDING
64,EP,B1,EP 2759595 B1,089-968-249-079-927,2016-09-14,2016,EP 13305082 A,2013-01-24,EP 13305082 A,2013-01-24,Composition comprising an encapsulated antagomir,,PIERRE FABRE MÉDICAMENT S A S;;FUNDACIÓ HOSPITAL UNI VALL D HEBRON INST DE RECERCA,ASIN MIGUEL-ANGEL;;FERRET EULALIA;;PEREZ AMADEO;;GARCIA-DORADO GARCIA ANTONIO DAVID;;VERT IGNASI BARBA;;RODRIGUEZ SINOVAS ANTONIO;;GOTARDA NEUS BELLERA,,https://lens.org/089-968-249-079-927,Granted Patent,yes,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N15/113;;A61K31/712,,3,0,,,"BONAUER ANGELIKA ET AL: ""MicroRNA-92a controls angiogenesis and functional recovery of ischemic tissues in mice"", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, vol. 324, no. 5935, 26 June 2009 (2009-06-26), pages 1710-1713, XP002575234, ISSN: 0036-8075;;D'ANGELO IVANA ET AL: ""Improved delivery of angiogenesis inhibitors from PLGA:poloxamer blend micro- and nanoparticles."", JOURNAL OF MICROENCAPSULATION 2010, vol. 27, no. 1, 2010, pages 57-66, XP002700281, ISSN: 1464-5246;;PANYAM J ET AL: ""Biodegradable nanoparticles for drug and gene delivery to cells and tissue"", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER BV, AMSTERDAM, NL, vol. 55, no. 3, 24 February 2003 (2003-02-24), pages 329-347, XP008096954, ISSN: 0169-409X, DOI: 10.1016/S0169-409X(02)00228-4",ACTIVE
65,EP,A1,EP 3746236 A1,054-937-727-209-166,2020-12-09,2020,EP 19747971 A,2019-01-17,US 201815887601 A;;US 2019/0013917 W,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,,GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,,https://lens.org/054-937-727-209-166,Patent Application,yes,0,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/06;;B22C9/22;;B22D25/02;;B28B1/00;;B33Y80/00,,0,0,,,,PENDING
66,US,A1,US 2019/0240726 A1,014-570-581-677-207,2019-08-08,2019,US 201815887601 A,2018-02-02,US 201815887601 A,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,"The present disclosure generally relates to integrated core-shell investment casting molds that provide tongue or groove structures corresponding, respectively, to groove or tongue structures in the surface of the turbine blade or stator vane, including in locations that are otherwise inaccessible. The groove and tongue structures also provide a pathway to restrict cooling flow between turbine blades to the flowpath.",GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,GENERAL ELECTRIC COMPANY (2018-01-09),https://lens.org/014-570-581-677-207,Patent Application,yes,0,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/22;;B22D29/00;;B28B1/00;;B33Y10/00;;B33Y80/00;;F01D5/18;;F01D9/02,,0,0,,,,ACTIVE
67,US,A1,US 2021/0308747 A1,065-822-904-876-381,2021-10-07,2021,US 202117350376 A,2021-06-17,US 202117350376 A;;US 201815887601 A,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,"Integrated core-shell investment casting molds that provide tongue or groove structures corresponding, respectively, to groove or tongue structures in the surface of the turbine blade or stator vane, including in locations that are otherwise inaccessible provide a pathway to restrict cooling flow between turbine blades to the flowpath.",GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,,https://lens.org/065-822-904-876-381,Patent Application,yes,13,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/22;;B22D29/00;;B28B1/00;;B33Y10/00;;B33Y80/00;;F01D5/18;;F01D9/02,,0,0,,,,DISCONTINUED
68,WO,A1,WO 2019/152204 A1,055-780-396-756-395,2019-08-08,2019,US 2019/0013917 W,2019-01-17,US 201815887601 A,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,"The present disclosure generally relates to integrated core-shell investment casting molds that provide tongue or groove structures corresponding, respectively, to groove or tongue structures in the surface of the turbine blade or stator vane, including in locations that are otherwise inaccessible. The groove and tongue structures also provide a pathway to restrict cooling flow between turbine blades to the flowpath.",GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,,https://lens.org/055-780-396-756-395,Patent Application,yes,19,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/06;;B22C9/22;;B22D25/02;;B28B1/00;;B33Y80/00,,1,0,,,See also references of EP 3746236A4,PENDING
69,US,B2,US 11130170 B2,158-742-881-520-156,2021-09-28,2021,US 201815887601 A,2018-02-02,US 201815887601 A,2018-02-02,Integrated casting core-shell structure for making cast component with novel cooling hole architecture,"Integrated core-shell investment casting molds that provide tongue or groove structures corresponding, respectively, to groove or tongue structures in the surface of the turbine blade or stator vane, including in locations that are otherwise inaccessible provide a pathway to restrict cooling flow between turbine blades to the flowpath.",GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,GENERAL ELECTRIC COMPANY (2018-01-09),https://lens.org/158-742-881-520-156,Granted Patent,yes,26,2,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/22;;B22D29/00;;B28B1/00;;B33Y10/00;;B33Y80/00;;C30B29/02;;F01D5/18;;F01D9/02,,1,0,,,"International Search Report Corresponding to Application No. PCT/US2018/037317 dated Sep. 11, 2018.",ACTIVE
70,US,S,US D0936230 S,017-388-465-763-149,2021-11-16,2021,US 201929678535 F,2019-01-29,US 201929678535 F,2019-01-29,Medical treatment cart,,ULTHERA INC,PROUT BRIAN LEE;;BARBA RICARDO M;;RAO RAHUL R;;SPRINGER LUKE DAVID;;CLARRIDGE KEVIN A;;POSCH ELLEN S;;MINNIS SYDNEY T;;DIENER ALEXANDER MICHAEL,ULTHERA INC (2016-07-13),https://lens.org/017-388-465-763-149,Design Right,no,102,5,3,3,0,,,2402;;D24/185,0,0,,,,ACTIVE
71,CN,A,CN 111683764 A,014-528-220-481-074,2020-09-18,2020,CN 201980011322 A,2019-01-17,US 201815887601 A;;US 2019/0013917 W,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,"The present disclosure generally relates to integrated core-shell investment casting molds that provide tongue or groove structures corresponding, respectively, to groove or tongue structures in the surface of the turbine blade or stator vane, including in locations that are otherwise inaccessible. The groove and tongue structures also provide a pathway to restrict cooling flow between turbine blades to the flowpath.",GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,,https://lens.org/014-528-220-481-074,Patent Application,no,6,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/06;;B22C9/22;;B22D25/02;;B28B1/00;;B33Y80/00,,0,0,,,,ACTIVE
72,EP,A4,EP 3746236 A4,109-950-641-100-08X,2021-10-20,2021,EP 19747971 A,2019-01-17,US 201815887601 A;;US 2019/0013917 W,2018-02-02,INTEGRATED CASTING CORE-SHELL STRUCTURE FOR MAKING CAST COMPONENT WITH NOVEL COOLING HOLE ARCHITECTURE,,GEN ELECTRIC,GARAY GREGORY TERRENCE;;DUBELMAN MEREDITH;;YANG XI;;PANG TINGFAN;;COLE MICHAEL SCOTT;;PRZESLAWSKI BRIAN DAVID;;KONITZER DOUGLAS GERARD;;BARBA NICOLE;;GALLIER KIRK;;KEITH BRIAN,,https://lens.org/109-950-641-100-08X,Search Report,no,4,0,8,8,0,B22D29/002;;B22C9/22;;B28B7/342;;B28B7/346;;B33Y80/00;;F05D2230/211;;F05D2300/607;;F05D2250/294;;F01D11/006;;F01D5/20;;F05D2260/202;;F05D2260/201;;F05D2240/81;;F05D2260/204;;F01D5/189;;F05D2240/11;;F01D5/186;;F01D5/187;;F05D2260/36;;C30B29/52;;C30B11/00;;B22C9/22;;B22D29/002;;B28B1/001;;B33Y10/00;;F05D2300/10;;F01D5/18;;F01D9/02;;C30B29/02;;F05D2220/32;;B33Y80/00;;F01D9/041;;F01D11/008;;F01D5/22,B22C9/22;;B22D29/00;;B28B7/34;;B33Y80/00;;C30B11/00;;C30B29/52;;F01D5/18;;F01D5/20;;F01D11/00,,1,0,,,See also references of WO 2019152204A1,PENDING
73,WO,A1,WO 2023/222123 A1,050-857-538-937-433,2023-11-23,2023,CN 2023095343 W,2023-05-19,US 202263365038 P;;US 202263365041 P,2022-05-20,ARTICLE CONTAINING A WASHABLE ADHESIVE COMPOSITION,"The present disclosure provides an article. In an embodiment, the article includes a first substrate and an adhesive layer in contact with the first substrate. The adhesive layer contains an adhesive composition. The adhesive composition includes (i) an acrylic polymer composed of polymerized units of (a) a first monomer that is a C 4 ‐C 18 alkyl acrylate and (b) a second monomer selected from acrylic acid, methacrylic acid, and a C 1 ‐C 3 alkyl acrylate optionally containing a hydroxyl group. The adhesive composition also includes (ii) at least one inorganic neutralizer, and (iii) at least one surfactant. The article includes a second substrate in contact with the adhesive layer.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS;;JANKO PAVEL;;PEERA ASGHAR A;;MALLOZZI MICHAEL A;;ANDREU EDUARDO BARBA;;ZOLYNSKI SARAH R;;UHL ISABELLE;;WANG XINHONG,JANKO PAVEL;;PEERA ASGHAR A;;MALLOZZI MICHAEL A;;ANDREU EDUARDO BARBA;;ZOLYNSKI SARAH R;;UHL ISABELLE;;WANG XINHONG;;LIU FANG;;KEELY DAVID R;;LI LI,,https://lens.org/050-857-538-937-433,Patent Application,yes,6,0,3,5,0,E01C13/08;;C09D5/008;;C08J7/0427;;C08J7/056;;C08J2433/06;;C08J2323/02;;C09D133/064,C09J133/08;;C09J7/21;;C09J133/10;;C09J133/12,,0,0,,,,PENDING
74,FR,A1,FR 3135726 A1,062-341-135-300-452,2023-11-24,2023,FR 2304978 A,2023-05-19,US 202263365038 P;;US 202263365041 P,2022-05-20,ARTICLE CONTAINING A WASHABLE ADHESIVE COMPOSITION - ARTICLE CONTENANT UNE COMPOSITION D’ADHÉSIF LAVABLE,"The present disclosure provides an article. In an embodiment, the article includes a first substrate and an adhesive layer in contact with the first substrate. The adhesive layer contains an adhesive composition. The adhesive composition includes (i) an acrylic polymer composed of polymerized units of (a) a first monomer that is a C4-C18 alkyl acrylate and (b) a second monomer selected from acrylic acid, methacrylic acid, and a C1-C3 alkyl acrylate optionally containing a hydroxyl group. The adhesive composition also includes (ii) at least one inorganic neutralizer, and (iii) at least one surfactant. The article includes a second substrate in contact with the adhesive layer.",DOW GLOBAL TECHNOLOGIES LLC;;ROHM & HAAS,JANKO PAVEL;;PEERA ASGHAR A;;MALLOZZI MICHAEL A;;ANDREU EDUARDO BARBA;;ZOLYNSKI SARAH R;;UHL ISABELLE;;WANG XINHONG;;LIU FANG;;KEELY DAVID R;;LI LI,,https://lens.org/062-341-135-300-452,Patent Application,no,0,0,3,5,0,E01C13/08;;C09D5/008;;C08J7/0427;;C08J7/056;;C08J2433/06;;C08J2323/02;;C09D133/064,C09J133/06;;C09J121/02;;C09J133/02,,0,0,,,,PENDING
75,CA,A1,CA 2754794 A1,077-930-710-386-556,2010-09-16,2010,CA 2754794 A,2010-03-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/077-930-710-386-556,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,DISCONTINUED
76,MA,B1,MA 33242 B1,103-204-960-067-763,2012-05-02,2012,MA 34246 A,2011-10-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,مركبات لعلاج اضطرابات الاستقلاب,"L'invention concerne des composés thérapeutiques représentés par la formule (i), qui présentent une activité d'agonistes de gpr119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.",PROSIDION LTD,BARBA OSCAR;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;DAVIS SUSAN HELEN;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;WITHALL DAVID MATTHEW;;SWAIN SIMON ANDREW,,https://lens.org/103-204-960-067-763,Granted Patent,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,ACTIVE
77,US,A1,US 2012/0040953 A1,147-690-066-796-892,2012-02-16,2012,US 201013255536 A,2010-03-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,Compounds for the Treatment of Metabolic Disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW;;PROSIDION LTD,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,PROSIDION LIMITED (2011-09-21),https://lens.org/147-690-066-796-892,Patent Application,yes,0,2,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,A61K31/506;;A61K31/4545;;A61K31/501;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/10;;C07D401/14;;C07D413/14,514/210.18;;514/252.03;;514/275;;514/316;;514/318;;544/238;;544/331;;546/187;;546/194,0,0,,,,DISCONTINUED
78,CN,A,CN 102395584 A,079-390-693-982-88X,2012-03-28,2012,CN 201080016428 A,2010-03-12,GB 2010050442 W;;GB 0904287 A,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,OSCAR BARBA;;HELEN DAVIS SUSAN;;THOR FYFE MATTHEW COLIN;;PERPETUA JEEVARATNAM REVATHY;;LESLEY SCHOFIELD KAREN;;THOMAS STAROSKE;;WILLIAM STEWART ALAN JOHN;;ANDREW SWAIN SIMON;;MATTHEW WITHALL DAVID,,https://lens.org/079-390-693-982-88X,Patent Application,no,4,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,DISCONTINUED
79,KR,A,KR 20110130476 A,082-261-612-483-729,2011-12-05,2011,KR 20117024020 A,2010-03-12,GB 0904287 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/082-261-612-483-729,Patent Application,no,0,1,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61K31/4427;;A61P3/00,,0,0,,,,DISCONTINUED
80,ZA,B,ZA 201107446 B,084-850-772-917-31X,2012-06-27,2012,ZA 201107446 A,2011-10-11,GB 0904287 A;;GB 2010050442 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;FYFE MATTHEW COLLIN THOR;;SCHOFIELD KAREN LESLEY;;STEWARD ALAN JOHN WILLIAM;;WITHALL DAVID MATTHEW;;JEEVARATHNAM REVATHY PERPETUA;;STAROSKE THOMAS;;SWAIN SIMONS ANDREW;;DAVIS SUSAN HELEN,,https://lens.org/084-850-772-917-31X,Granted Patent,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
81,MX,A,MX 2011009491 A,080-985-759-480-451,2011-10-11,2011,MX 2011009491 A,2010-03-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS.,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,FYFE MATTHEW COLIN THOR;;SCHOFIELD KAREN LESLEY;;BARBA OSCAR;;SWAIN SIMON ANDREW;;JEEVARATNAM REVATHY PERPETUA;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;WITHALL DAVID MATTHEW;;DAVIS SUSAN HELEN,,https://lens.org/080-985-759-480-451,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,PENDING
82,AU,A1,AU 2010/222673 A1,172-065-680-092-361,2011-11-03,2011,AU 2010/222673 A,2010-03-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,OSCAR BARBA;;HELEN DAVIS SUSAN;;THOR FYFE MATTHEW COLIN;;PERPETUA JEEVARATNAM REVATHY;;LESLEY SCHOFIELD KAREN;;THOMAS STAROSKE;;WILLIAM STEWART ALAN JOHN;;ANDREW SWAIN SIMON;;MATTHEW WITHALL DAVID,,https://lens.org/172-065-680-092-361,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,DISCONTINUED
83,BR,A2,BR PI1009781 A2,133-065-392-259-281,2016-03-08,2016,BR PI1009781 A,2010-03-12,GB 2010050442 W;;GB 0904287 A,2009-03-12,"compostos para o tratamento de distúrbios metabólicos, composição farmacêutica que os compreende e uso dos mesmos",,PROSIDION LTD,STEWART ALAN JOHN WILLIAM;;WITHALL DAVID MATTHEW;;SCHOFIELD KAREN LESLEY;;FYFE MATTHEW COLIN THOR;;BARBA OSCAR;;JEEVARATNAM REVATHY PERPETUA;;SWAIN SIMON ANDREW;;DAVIS SUSAN HELEN;;STAROSKE THOMAS,,https://lens.org/133-065-392-259-281,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,A61K31/4245;;C07D413/14;;A61P3/10,,0,0,,,,DISCONTINUED
84,EP,A1,EP 2406256 A1,028-361-566-777-426,2012-01-18,2012,EP 10709926 A,2010-03-12,GB 2010050442 W;;GB 0904287 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/028-361-566-777-426,Patent Application,yes,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,DISCONTINUED
85,WO,A1,WO 2010/103335 A1,121-286-608-966-713,2010-09-16,2010,GB 2010050442 W,2010-03-12,GB 0904287 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD;;BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/121-286-608-966-713,Patent Application,yes,35,7,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,10,6,007-854-898-735-007;;101-195-126-039-563;;041-211-316-532-650;;122-017-674-921-151;;047-842-597-267-580;;020-034-478-792-563,17562364;;10.1016/j.bmcl.2007.05.087;;10.1016/j.bmcl.2007.07.081;;17822893;;11733510;;10.1074/jbc.m107384200;;10.1016/s0960-894x(99)00398-4;;10476879;;10.1126/science.2171146;;2171146;;2535825;;10.2337/diabetes.38.1.44;;10.2337/diab.38.1.44,"BRACKES, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 2005 - 2012;;PEI, J. MED. CHEM., vol. 50, no. 8, 2007, pages 1983 - 1987;;COX, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 4579 - 4583;;WRIGHT, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 5638 - 5642;;T.W. GREENE; P.G.M. WUTS: ""Protective Groups in Organic Chemistry"", 1991, WILEY-INTERSCIENCE;;MIRET J. J. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6881 - 6887;;CAMPBELL R.M. ET AL., BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2413 - 2418;;KING K. ET AL., SCIENCE, vol. 250, 1990, pages 121 - 123;;AGATEP, R. ET AL.: ""Technical Tips Online, Trends Journals"", 1998, ELSEVIER, article ""Transformation of Saccharomyces cerevisiae by the lithium acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol"";;ZHANG HJ; WALSETH TF; ROBERTSON RP.: ""Insulin secretion and cAMP metabolism in HIT cells. Reciprocal and serial passage-dependent relationships"", DIABETES., vol. 38, no. 1, January 1989 (1989-01-01), pages 44 - 8",PENDING
86,SG,A1,SG 174362 A1,126-888-023-706-406,2011-11-28,2011,SG 2011065794 A,2010-03-12,GB 0904287 A;;GB 2010050442 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,BARBA OSCAR;;DAVIS SUSAN HELEN;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/126-888-023-706-406,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,,,0,0,,,,PENDING
87,MX,A,MX 2015001840 A,058-655-154-781-500,2016-08-11,2016,MX 2015001840 A,2015-02-10,MX 2015001840 A,2015-02-10,PROCESS FOR PRODUCING POROUS METAL COMPOSITES WITH HYDROXYAPATITE FOR IMPLANTS AND THE METAL-HYDROXYAPATITE COMPOSITE.,"The present disclosure is related to the preparation, conditioning and consolidation of a mixture of ceramic and metallic powders processed in the right proportions, at precise temperatures and pressure, for making densified/sintered pieces with optimal mechanical and chemical properties. Once approved by the national and/or international health guidelines and after being machined for the necessary geometries, said pieces can be used as implants/prosthesis in the human body. The precursor/reactive materials are, for example, high purity HA hydroxyapatite powders, which can be purchased commercially and/or synthesized from precursor/reactive chemical liquids, and other metal powders; for example, high purity titanium (Ti or Ta), or a Ti6AI4V (biocompatible) alloy, or of other biodegradable metals/alloys.",INST POLITECNICO NACIONAL,SEBASTIÁN DÍAZ DE LA TORRE;;MARIANO CASAS LUNA;;DAVID JARAMILLO VIGUERAS;;MARÍA DEL ROCIO DE LA TORRE AGUILAR;;MARÍA CRISTINA PIÑA BARBA;;LADISLAV CELKO;;EDGAR BENJAMÍN MONTÚFAR JIMÉNEZ,,https://lens.org/058-655-154-781-500,Patent Application,no,0,1,2,2,0,,A61L27/12;;A61L27/00,,0,0,,,,ACTIVE
88,CN,A,CN 116018404 A,184-443-315-227-708,2023-04-25,2023,CN 202180038719 A,2021-03-26,US 202063000998 P;;IB 2021000231 W,2020-03-27,Defect interference viral genomes,"Methods of generating a defective interfering viral genome (DVG), defective interfering particles comprising the DVG, and methods and uses thereof.",PASTEUR INSTITUT,VIGNOZZI MATTEO;;MEYER BERND;;RAEZELL VIRGINIE;;LEVY LOIC;;BONHOROVA VALENTINA;;VALETTE THIERRY;;PIEPLU TOMASZ;;SENJULE DAVID;;BEGOU SEBASTIEN;;BLANK HOLGER;;PADIGAN NAGARAJU;;BARBA-SPATH GEORG;;SALEH MARIE-CLAIRE,,https://lens.org/184-443-315-227-708,Patent Application,no,0,0,11,11,0,C12N7/00;;C12N2770/20021;;C12N2770/20034;;C12N2770/24021;;C12N2770/24034;;C12N2770/32721;;C12N2770/32734;;C12N2770/36121;;C12N2770/36134;;C12N2770/32321;;C12N2770/32334;;Y02A50/30;;C12N7/00;;C12N2770/32334;;C12N2770/32734;;C12N2770/36121;;C12N2770/36134;;C12N2770/20021;;C12N2770/32721;;C12N2770/24034;;C12N2770/32321;;C12N2770/20034;;C12N2770/24021;;C12N7/00;;A61K39/12;;A61P31/12;;C12N2770/20021;;C12N2770/20034;;C12N2770/24021;;C12N2770/24034;;C12N2770/32321;;C12N2770/32334;;C12N2770/32721;;C12N2770/32734;;C12N2770/36121;;C12N2770/36134;;C12N7/00;;C12N2770/20021;;C12N2770/20034;;C12N2770/32321;;C12N2770/32334;;C12N2770/32721;;C12N2770/32734;;C12N2770/36121;;C12N2770/36134,C12N7/00,,0,0,,,,PENDING
89,MX,B,MX 365570 B,158-868-118-133-236,2019-05-17,2019,MX 2015001840 A,2015-02-10,MX 2015001840 A,2015-02-10,PROCESS FOR PRODUCING POROUS METAL COMPOSITES WITH HYDROXYAPATITE FOR IMPLANTS AND THE METAL-HYDROXYAPATITE COMPOSITE.,"The present disclosure is related to the preparation, conditioning and consolidation of a mixture of ceramic and metallic powders processed in the right proportions, at precise temperatures and pressure, for making densified/sintered pieces with optimal mechanical and chemical properties. Once approved by the national and/or international health guidelines and after being machined for the necessary geometries, said pieces can be used as implants/prosthesis in the human body. The precursor/reactive materials are, for example, high purity HA hydroxyapatite powders, which can be purchased commercially and/or synthesized from precursor/reactive chemical liquids, and other metal powders; for example, high purity titanium (Ti or Ta), or a Ti6AI4V (biocompatible) alloy, or of other biodegradable metals/alloys.",INST POLITECNICO NACIONAL,SEBASTIÁN DÍAZ DE LA TORRE;;MARIANO CASAS LUNA;;DAVID JARAMILLO VIGUERAS;;MARÍA DEL ROCIO DE LA TORRE AGUILAR;;MARÍA CRISTINA PIÑA BARBA;;LADISLAV CELKO;;EDGAR BENJAMÍN MONTÚFAR JIMÉNEZ,,https://lens.org/158-868-118-133-236,Granted Patent,no,0,0,2,2,0,,A61L27/12;;A61L27/00;;C01B25/32;;C04B35/447,,0,0,,,,ACTIVE
90,MA,B1,MA 33241 B1,022-287-736-233-755,2012-05-02,2012,MA 34245 A,2011-10-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,مركبات لعلاج اضطرابات الاستقلاب,"L'invention concerne des composés thérapeutiques qui présentent une activité d'agonistes de gpr119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2.",PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW;;FRY PETER TIMOTHY;;KRULLE THOMAS MARTIN;;STONEHOUSE DAVID FRENCH,,https://lens.org/022-287-736-233-755,Granted Patent,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,ACTIVE
91,TW,S,TW D204532 S,141-742-662-085-409,2020-05-01,2020,TW 108304494 F,2019-07-26,US 201929678535 F,2019-01-29,MEDICAL TREATMENT CART,【物品用途】;本設計物品係一種醫療車之外觀設計。;【設計說明】;本設計物品之要點在於形狀，其為一原創性和新穎性之設計。,美商優珊納有限公司;;ULTHERA INC,PROUT BRAIN LEE;;Ｍ BARBA RICARDO M;;Ｒ RAO RAHUL R;;SPRINGER LUKE DAVID;;Ａ CLARRIDGE KEVIN A;;Ｓ POSCH ELLEN S;;Ｔ MINNIS SYDNEY T;;DIENER ALEXANDER MICHAEL,,https://lens.org/141-742-662-085-409,Design Right,no,0,0,3,3,0,,,24-01,0,0,,,,ACTIVE
92,HK,A1,HK 1219753 A1,084-038-491-393-495,2017-04-13,2017,HK 16107653 A,2016-06-30,IB 2014058500 W;;EP 13305082 A,2013-01-24,COMPOSITION COMPRISING AN ENCAPSULATED ANTAGOMIR ANTAGOMIR,,PIERRE FABRE MEDICAMENT S A S;;FUND HOSPITAL UNIV VALL DHEBRON INST,MIGUEL-ANGEL ASIN M-A;;EULALIA FERRET E;;AMADEO PEREZ A;;NEUS BELLERA GOTARDA NB;;ANTONIO RODRIGUEZ SINOVAS A;;IGNASI BARBA VERT IB;;ANTONIO DAVID GARCIA-DORADO GARCIA AD-,,https://lens.org/084-038-491-393-495,Patent Application,no,0,0,21,21,0,C12N15/113;;C12N2310/113;;C12N2310/3231;;C12N2320/32;;A61P9/10;;A61P9/00;;A61K9/5031;;A61K31/7088;;C12N15/113;;A61K9/5031;;C12N15/113;;C12N2310/113;;C12N2320/32;;C12N2310/3231,C12N/;;A61K/,,0,0,,,,PENDING
93,BR,A2,BR PI1009783 A2,011-093-007-869-329,2016-03-08,2016,BR PI1009783 A,2010-03-12,GB 2010050441 W;;GB 0904285 A,2009-03-12,compostos para o tratamento de distúrbios metabólicos.,,PROSIDION LTD,STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;WITHALL DAVID MATTHEW;;SMYTH DONALD;;SCHOFIELD KAREN LESLEY;;FYFE MATTHEW COLIN THOR;;BARBA OSCAR;;FRY PETER TIMOTHY;;JEEVARATNAM REVATHY PERPETUA;;SWAIN SIMON ANDREW;;KRULLE THOMAS MARTIN;;STAROSKE THOMAS;;DUPREE TOM BANKSIA,,https://lens.org/011-093-007-869-329,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,DISCONTINUED
94,PE,A1,PE 20120356 A1,111-455-852-973-191,2012-04-16,2012,PE 2011001633 A,2010-03-12,GB 0904287 A,2009-03-12,COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS,"REFERIDA A UN COMPUESTO HETEROCICLICO DE FORMULA (I), DONDE p ES 1 O 2; Z ES N-C(O)OR4, N-C(O)NR4R5, N-CH2-FENILO, ENTRE OTROS; A ES UN GRUPO FENILO O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; B ES UN ANILLO HETEROARILO DE 5 MIEMBROS QUE CONTIENE UNO O MAS HETEROATOMOS SELECCIONADOS DE N, O Y S O UN ANILLO HETEROARILO DE 6 MIEMBROS QUE CONTIENE UNO O DOS ATOMOS DE NITROGENO; X ES O-CR6H, O, CR6H-O, ENTRE OTROS; R1 ES H, HALO, CIANO, ALQUILO C1-C4, ENTRE OTROS; q ES 1 O 2; R2 ES UN GRUPO (a) O UN GRUPO FENILO OPCIONALMENTE SUSTITUIDO CON HALO O PIRIDILO; R3 ES HALO O METILO; n ES 0 O 1; m ES 0, 1 O 2; R4 ES ALQUILO C2-C6, CICLOALQUILO C3-C6, ENTRE OTROS; R5 ES H O ALQUILO C1-C4; R6 ES H O ALQUILO C1-C2. SON COMPUESTOS PREFERIDOS: ESTER ISOPROPILICO DEL ACIDO 4-[5-(6-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-[3-(6-CLORO-PIRIDIN-3-IL)-[1,2,4]OXADIAZOL-5-ILMETOXI]-PIPERIDIN-1-CARBOXILICO, ESTER ISOPROPILICO DEL ACIDO 4-{(R)-1-[5-(2-CLOROPIRIMIDIN-5-IL)-[1,2,4]OXADIAZOL-3-IL]-ETOXI}-PIPERIDIN-1-CARBOXILICO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS TIENEN ACTIVIDAD COMO AGONISTA DEL RECEPTOR GPR119 Y COMO INHIBIDORES DE LA DPP-IV SIENDO UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS INCLUYENDO LA DIABETES TIPO II",PROSIDION LTD,BARBA OSCAR;;JEEVARATNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW;;FYFE MATTHEW COLIN THOR;;DAVIS SUSAN HELEN,,https://lens.org/111-455-852-973-191,Patent Application,no,0,0,18,18,0,C07D413/14;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/12;;A61P3/10;;C07D413/14;;A61K31/4427;;A61K31/4245;;C07D413/14,C07D413/14;;A61K31/4245;;A61P3/10,,0,0,,,,DISCONTINUED
95,WO,A1,WO 2010/103334 A1,030-804-034-361-085,2010-09-16,2010,GB 2010050441 W,2010-03-12,GB 0904285 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD;;BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/030-804-034-361-085,Patent Application,yes,34,13,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,10,6,078-016-257-189-686;;007-854-898-735-007;;101-195-126-039-563;;041-211-316-532-650;;122-017-674-921-151;;047-842-597-267-580,10.1517/17460441.3.4.403;;23489096;;17562364;;10.1016/j.bmcl.2007.05.087;;10.1016/j.bmcl.2007.07.081;;17822893;;11733510;;10.1074/jbc.m107384200;;10.1016/s0960-894x(99)00398-4;;10476879;;10.1126/science.2171146;;2171146,"FYFE M C T ET AL: ""GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity"", EXPERT OPINION ON DRUG DISCOVERY, INFORMA HEALTHCARE, LONDON, GB LNKD- DOI:10.1517/17460441.3.4.403, vol. 3, no. 4, 1 April 2008 (2008-04-01), pages 403 - 413, XP009118163, ISSN: 1746-0441;;BRACKES, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 2005 - 2012;;PEI, J. MED. CHEM., vol. 50, no. 8, 2007, pages 1983 - 1987;;COX, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 4579 - 4583;;WRIGHT, BIOORG. MED. CHEM. LETT., vol. 17, 2007, pages 5638 - 5642;;MIRET J. J. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6881 - 6887;;CAMPBELL R.M. ET AL., BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2413 - 2418;;KING K. ET AL., SCIENCE, vol. 250, 1990, pages 121 - 123;;AGATEP, R. ET AL.: ""Technical Tips Online, Trends Journals"", 1998, ELSEVIER, article ""Transformation of Saccharomyces cerevisiae by the lithium acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol"";;DIABETES., vol. 38, no. 1, January 1989 (1989-01-01), pages 44 - 8",PENDING
96,EP,A1,EP 2406251 A1,095-112-117-795-517,2012-01-18,2012,EP 10709053 A,2010-03-12,GB 2010050441 W;;GB 0904285 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/095-112-117-795-517,Patent Application,yes,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,DISCONTINUED
97,AU,A1,AU 2010/222672 A1,026-814-696-735-933,2011-11-03,2011,AU 2010/222672 A,2010-03-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,OSCAR BARBA;;BANKSIA DUPREE TOM;;TIMOTHY FRY PETER;;THOR FYFE MATTHEW COLIN;;PERPETUA JEEVARATNAM REVATHY;;MARTIN KRULLE THOMAS;;LESLEY SCHOFIELD KAREN;;DONALD SMYTH;;THOMAS STAROSKE;;WILLIAM STEWART ALAN JOHN;;FRENCH STONEHOUSE DAVID;;ANDREW SWAIN SIMON;;MATTHEW WITHALL DAVID,,https://lens.org/026-814-696-735-933,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,DISCONTINUED
98,SG,A1,SG 174363 A1,034-950-597-523-886,2011-10-28,2011,SG 2011065802 A,2010-03-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/034-950-597-523-886,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,,,0,0,,,,PENDING
99,KR,A,KR 20110133045 A,171-334-256-017-641,2011-12-09,2011,KR 20117024019 A,2010-03-12,GB 0904285 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/171-334-256-017-641,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D401/14;;A61K31/506;;A61P3/10;;C07D413/14,,0,0,,,,DISCONTINUED
100,MX,A,MX 2011009493 A,058-888-995-548-815,2011-10-11,2011,MX 2011009493 A,2010-03-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS.,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,SCHOFIELD KAREN LESLEY;;BARBA OSCAR;;KRULLE THOMAS MARTIN;;SMYTH DONALD;;SWAIN SIMON ANDREW;;JEEVARATNAM REVATHY PERPETUA;;STONEHOUSE DAVID FRENCH;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;WITHALL DAVID MATTHEW;;FYFE MATTHEW COLIN THOR,,https://lens.org/058-888-995-548-815,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,PENDING
101,PE,A1,PE 20120218 A1,157-061-953-224-146,2012-03-19,2012,PE 2011001638 A,2010-03-12,GB 0904285 A,2009-03-12,COMPUESTOS PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS,"SE REFIERE A COMPUESTOS HETEROCICLICOS DE FORMULA (I) DONDE Z ES C(O)OR4, HETEROARILO, ENTRE OTROS, EN DONDE R4 ES ALQUILO(C2-C6) O CICLOALQUILO(C3-C6); X ES O, NR7 O CR6R66, EN DONDE R6 Y R66 SON CADA UNO H, F O ALQUILO(C1-C4); R7 ES H O ALQUILO(C1-C4); Y ES ALQUILENO(C2-C4) OPCIONALMENTE SUSTITUIDO CON F O METILO; A ES FENILO O UN ANILLO HETEROAROMATICO DE 6 MIEMBROS QUE CONTIENE 1 A 2 ATOMOS DE N; R1 ES H, HALO, CN, ALQUILO(C1-C4) O HALOALQUILO(C1-C4); R2 ES FENILO SUSTITUIDO OPCIONALMENTE CON HALO, PIRIDILO SUSTITUIDO OPCIONALMENTE CON HALO O METILO, ENTRE OTROS; p ES 1 O 2; q ES 1 O 2. SON COMPUESTOS PREFERIDOS: 1-[(3S,4S)-4-AMINO-1-(5-{(R)-3-[1-(5-CLOROPIRIMIDIN-2-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-2-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, 1-[(3S,4S)-4-AMINO-1-(6-{(R)-3-[1-(3-ISOPROPIL-[1,2,4]OXADIAZOL-5-IL)PIPERIDIN-4-IL]BUTOXI}PIRIMIDIN-4-IL)PIRROLIDIN-3-IL]PIPERIDIN-2-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON AGONISTAS DEL RECEPTOR ACOPLADO A PROTEINA G 119 (GPR119) SIENDO UTILES EN EL TRATAMIENTO DE DIABETES TIPO II, OBESIDAD, SINDROME METABOLICO, HIPERLIPIDEMIA",PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/157-061-953-224-146,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,A61K31/506;;A61P3/10;;C07D403/12,,0,0,,,,DISCONTINUED
102,US,A1,US 2012/0059014 A1,104-009-489-533-904,2012-03-08,2012,US 201013255531 A,2010-03-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,Compounds for the Treatment of Metabolic Disorders,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW;;PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,PROSIDION LIMITED (2011-09-21),https://lens.org/104-009-489-533-904,Patent Application,no,0,3,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,A61K31/506;;A61K31/4545;;A61K31/501;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P3/10;;A61P7/00;;A61P9/12;;C07D401/14;;C07D413/14,514/252.03;;544/296;;514/273;;546/187;;514/316;;544/319;;514/269;;544/321;;544/238,0,0,,,,DISCONTINUED
103,WO,A1,WO 2023/168006 A1,059-266-710-072-80X,2023-09-07,2023,US 2023/0014386 W,2023-03-02,US 202263315600 P,2022-03-02,"COMPOSITIONS COMPRISING EXOSOMES, GROWTH FACTORS AND FRAGMENTS OF MESENCHYMAL STEM CELLS FOR USE IN THE TREATMENT OF SKIN","Compositions comprising exosomes, growth factors, and fragments of mesenchymal stem cells (MSCs), and their use for the cosmetic and/or therapeutic treatment of skin are provided. Methods for preparing the compositions are also provided.",CRYOGEN LLC;;CENTRO DE BIOTECNOLOGIA SANTER SC;;MARTINEZ ALVAREZ ILIANY ANNEL,MARTINEZ ALVAREZ ILIANY ANNEL;;RODRIGUEZ DAVID URIBE;;MONTENEGRO JOSE ALEJANDRO ROBERT;;RICO DORA YURIDIA GUTIERREZ;;SALCEDO BARBA MIGUEL ERNESTO;;BARAJAS TORRES REYNA LUCIA;;CRIOLLO VINEUEZA VALERIA MARGARITA;;THOMPSON RONNIE AL,,https://lens.org/059-266-710-072-80X,Patent Application,yes,5,0,2,2,0,A61K8/14;;A61K8/64;;A61K8/4953;;A61K8/34;;A61K8/983;;A61Q19/08;;A61K35/28;;A61K38/18;;A61P17/00;;A61P17/02;;A61K36/185;;A61P17/02;;A61K8/981;;A61K9/0014;;A61K35/28;;A61K45/06;;A61K2800/805;;A61Q17/04;;A61Q19/00,A61K8/14;;A61K8/34;;A61K8/49;;A61K8/64;;A61K8/98;;A61K35/28;;A61K38/18;;A61P17/00;;A61P17/02;;A61Q19/08,,21,10,018-343-669-068-380;;068-838-437-672-317;;029-521-114-763-900;;130-093-807-800-869;;029-807-498-842-918;;063-166-356-642-713;;111-706-527-292-054;;099-626-219-321-041;;040-281-087-357-904;;008-087-951-915-608,33898436;;pmc8058372;;10.3389/fcell.2021.647012;;30988996;;pmc6461301;;10.3831/kpi.2019.22.001;;10.1046/j.1365-2133.2003.05164.x;;12588374;;23736003;;10.1038/aps.2013.50;;pmc4002895;;10.3727/096368910x;;21396235;;10.1016/j.biopha.2020.110789;;33152947;;10.1155/2013/519126;;pmc3867954;;24381938;;10.1155/2016/7315830;;pmc4761676;;27057176;;pmc3179613;;10.1089/ten.tea.2011.0036;;21563860;;pmc2956268;;10.1016/j.biomaterials.2010.07.083;;20728934,"QUIÑONES-VICO MARÍA I. ET AL: ""The Role of Exosomes Derived From Mesenchymal Stromal Cells in Dermatology"", FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 9, 7 April 2021 (2021-04-07), XP093050699, Retrieved from the Internet <URL:https://www.frontiersin.org/articles/10.3389/fcell.2021.647012/full> DOI: 10.3389/fcell.2021.647012;;RAHIMI RAHIMI VAFA VAFA BARADARAN BARADARAN ET AL: ""A Pharmacological Review on Portulaca oleracea L.: Focusing on Anti-Inflammatory, Anti- Oxidant, Immuno-Modulatory and Antitumor Activities"", JOURNAL OF PHARMACOPUNCTURE, 1 March 2019 (2019-03-01), Korea (South), pages 7 - 15, XP093050860, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461301/pdf/2093-6966-v22-n03-007.pdf> [retrieved on 20230531], DOI: 10.3831/KPI.2019.22.001;;C-H WU ET AL: ""Wound healing effects of porcine placental extracts on rats with thermal injury"", BRITISH JOURNAL OF DERMATOLOGY, JOHN WILEY, HOBOKEN, USA, vol. 148, no. 2, 17 February 2003 (2003-02-17), pages 236 - 245, XP071157437, ISSN: 0007-0963, DOI: 10.1046/J.1365-2133.2003.05164.X;;WEI ET AL., ACTA PHARMACOLOGICA SINICA, vol. 34, 2013, pages 747 - 754;;LAVOIEROSU-MYLES, J. NEUROL. SCI., vol. 324, 2013, pages 1 - 9;;DING ET AL., CELL TRANSPLANTATION, vol. 20, 2011, pages 5 - 14;;SPECS ET AL., STEM CELL RESEARCH & THERAPY, vol. 7, 2016, pages 125;;WATT ET AL., BR. MED. BULL., vol. 108, 2013, pages 25 - 53;;LIEBERMAN, PHARMACEUTICAL DOSAGE FORMS, 1992;;LLOYD, THE ART, SCIENCE AND TECHNOLOGY OF PHARMACEUTICAL COMPOUNDING, 1999;;""Remington: The Science and Practice of Pharmacy"", 2003;;PICKAR, DOSAGE CALCULATIONS, 1999;;ALLEN: ""Remington - The Science and Practice of Pharmacy"", 2012, THE PHARMACEUTICAL PRESS;;KIM ET AL., BIOMED. &PHARMACOTHER., vol. 131, 2020, pages 110789;;KIM ET AL., BIOCHEM. BIOPHYS. REP., vol. 16, 2018, pages 96 - 102;;ZHOU ET AL., BIOMED. RES. INT'L., 2013, pages 519126;;XU ET AL., STEM CELLS INT'L., 2016, pages 7315830;;AGRAWAL ET AL., TISSUE ENG., vol. 17, 2011, pages 2435 - 2443;;REING ET AL., BIOMATER., vol. 31, no. 33, 2010, pages 8626 - 8633;;KIM ET AL., BIOMED. & PHARMACOTHER., vol. 131, 2020, pages 110789;;ZHOU ET AL., BIOMED. RES. ΣNT'L., 2013, pages 519126",PENDING
104,US,A1,US 2023/0277439 A1,138-798-021-580-607,2023-09-07,2023,US 202318116758 A,2023-03-02,US 202318116758 A;;US 202263315600 P,2022-03-02,COMPOSITIONS AND METHODS OF USE FOR THE TREATMENT OF SKIN,Compositions for the cosmetic and/or therapeutic treatment of skin are provided. Methods for preparing the compositions and methods for using the compositions for the treatment of skin are also provided.,CRYOGEN LLC;;CENTRO DE BIOTECNOLOGIA SANTER SC,RODRIGUEZ DAVID URIBE;;MONTENEGRO JOSE ALEJANDRO ROBERT;;RICO DORA YURIDIA GUTIERREZ;;SALCEDO BARBA MIGUEL ERNESTO;;BARAJAS TORRES REYNA LUCIA;;CRIOLLO VINUEZA VALERIA MARGARITA;;THOMPSON RONNIE AL;;MARTINEZ ALVAREZ LLIANY ANNEL,,https://lens.org/138-798-021-580-607,Patent Application,yes,0,0,2,2,0,A61K8/14;;A61K8/64;;A61K8/4953;;A61K8/34;;A61K8/983;;A61Q19/08;;A61K35/28;;A61K38/18;;A61P17/00;;A61P17/02;;A61K36/185;;A61P17/02;;A61K8/981;;A61K9/0014;;A61K35/28;;A61K45/06;;A61K2800/805;;A61Q17/04;;A61Q19/00,A61K8/98;;A61K35/28;;A61K45/06;;A61P17/02;;A61Q17/04;;A61Q19/00,,0,0,,,,DISCONTINUED
105,CN,A,CN 102395578 A,176-843-890-368-841,2012-03-28,2012,CN 201080017147 A,2010-03-12,GB 2010050441 W;;GB 0904285 A,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,OSCAR BARBA;;BANKSIA DUPREE TOM;;TIMOTHY FRY PETER;;THOR FYFE MATTHEW COLIN;;PERPETUA JEEVARATNAM REVATHY;;MARTIN KRULLE THOMAS;;LESLEY SCHOFIELD KAREN;;DONALD SMYTH;;THOMAS STAROSKE;;WILLIAM STEWART ALAN JOHN;;FRENCH STONEHOUSE DAVID;;ANDREW SWAIN SIMON;;MATTHEW WITHALL DAVID,,https://lens.org/176-843-890-368-841,Patent Application,no,2,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,1,1,078-016-257-189-686,10.1517/17460441.3.4.403;;23489096,"MATTEW CT FYFE ET AL.: ""GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity"", 《EXPERT OPINION ON DRUG DISCOVERY》",DISCONTINUED
106,CA,A1,CA 2754791 A1,022-200-807-616-661,2010-09-16,2010,CA 2754791 A,2010-03-12,GB 0904285 A;;GB 2010050441 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds of the following formula (I) which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,PROSIDION LTD,BARBA OSCAR;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STAROSKE THOMAS;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/022-200-807-616-661,Patent Application,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,C07D403/12;;A61K31/506;;A61P3/10,,0,0,,,,DISCONTINUED
107,ZA,B,ZA 201107449 B,114-551-094-684-786,2012-06-27,2012,ZA 201107449 A,2011-10-11,GB 0904285 A;;GB 2010050441 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;JEEVARATHNAM REVATHY PERPETUA;;SCHOFIELD KAREN LESLEY;;STAROSKE THOMAS;;STONEHOUSE DAVID FRENCH;;WITHALL DAVID MATTHEW;;FYFE MATTHEW COLLIN THOR;;KRULLE THOMAS MARTIN;;SMYTH DONALD;;STEWARD ALAN JOHN WILLIAM;;DUPREE TOM BANKSIA;;SWAIN SIMONS ANDREW,,https://lens.org/114-551-094-684-786,Granted Patent,no,0,0,18,18,0,C07D403/12;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P7/00;;A61P9/12;;A61P3/10;;C07D401/14;;C07D413/14;;A61K31/506;;C07D403/12,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
108,ES,B1,ES 2048030 B1,021-187-441-103-027,1994-10-01,1994,ES 9101615 A,1991-07-10,ES 9101615 A,1991-07-10,CONTENEDOR ANTIINCENDIOS DE PAPEL Y CARTON USADO DESTINADO A LA VIA PUBLICA.,"CONTENEDOR ANTIINCENDIOS DE PAPEL Y CARTON USADO DESTINADO A LA VIA PUBLICA. LA INVENCION SE REFIERE A UN NUEVO TIPO DE CONTENEDOR ANTIINCENDIOS DESTINADO A LA VIA PUBLICA. SE PRETENDE DISMINUIR EL RIESGO DE FUEGO, ACCIDENTAL O INTENCIONADO, EN CONTENEDORES DE UNA RED DE RECOGIDA DE PAPELOTE. LA PRESENTE INVENCION NO TRATA DE APAGAR O AHOGAR LA LLAMA PRODUCIDA EN EL INTERIOR DEL CONTENEDOR SINO DE EVITAR QUE EL PAPEL PRENDA, HACIENDOLO PASAR ANTES DE ALOJARSE EN EL CONTENEDOR POR UNA PRECAMARA (1) DONDE ES ASFIXIADO Y APLASTADO HASTA APAGARSE. TODO ELLO SE CONSIGUE GRACIAS A UN MECANISMO (2) ACCIONADO MEDIANTE UN PEDAL EXTERNO (8) Y A UN CERRADO HERMETICO DE LA PRECAMARA Y DE TODO EL CONTENEDOR.",UNIV POLITECNICA DE BARCELONA,TADEUSZ BOGUMIL FELIKS;;BARBA I MUNDO ROMAN;;CARBO I BECH ALBERT;;DE LAS HERAS JIMENEZ SALVADOR;;DINARES I ARGEMI MARIAN;;GARELL I RAICH JOAN;;GONZALEZ DIEZ DAVID;;PASCUAL I IZQUIERDO JOSE M;;UMBERT I MONPEAT TONI,,https://lens.org/021-187-441-103-027,Granted Patent,no,0,0,2,2,0,Y02W30/64,B65D43/26;;B65F1/16,,0,0,,,,EXPIRED
109,GB,A,GB 2488360 A,075-876-994-988-681,2012-08-29,2012,GB 201103283 A,2011-02-25,GB 201103283 A,2011-02-25,Heterocyclic GPCR agonists,"Heterocyclic GPCR agonists Compounds of formula (I) as agonists of GPR119 for use in the treatment of metabolic disorders, including type II diabetes, metabolic syndrome (syndrome X), impaired glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels or hypertension. Within formula (I) A is a para-substituted phenyl or para-substituted 6-membered heteroaryl ring containing 1-3 nitrogen atoms; R2 is , or an optionally substituted phenyl, pyridyl, N-pyridonyl or N-pyrazolyl; Z is -C(O)OR4, -C(O)R4, -S(O)2R4, -S(O)2N(C1-3alkyl)R4, heteroaryl or -CH2-heteroaryl and when p and q are both 0, Z can also be -CH2-phenyl wherein the phenyl is optionally substituted; X is selected from CR5H, O, NR6 in which R5 and R6 are independently hydrogen or C1-2alkyl; R1, R3, R4 and R11 are each independently substitutents; Y is Y1 or W-Y1 where W is a 5 membered heteroaryl ring containing one or more heteroatoms selected from N, O and S and Y1 is selected from CR7H, O and NR8 wherein R7 and R8 are substituents, provided that when Y is W-Y1, X is O and Y1 is CR7H, when Y1 is NR8, X is CR5H and when X is O or NR6, Y1 is CR7H; R9 and R10 are each independently H, halo, C1-2alkyl, C1-2haloalkyl, C1-3alkoxy or hydroxyl; or R9 and R10 are joined to form an azabicyclo[3.3.1]nonane, a 3-oxa-7-azabicyclo[3.3.1]nonane or an aqzabicyclo[3.2.1]octane; m is 0, 1 or 2, n is 0 or 1; p and q are each 0, 1 or 2 provided that 0â ¤p+qâ ¤2 and r is 1 or 2. Also outlined are compounds where Z is -C(O)R12; where R12 is -NHC(O)R13 or â NHC(NH)R13 and R13 is a substitutent. Compounds having the stereochemistry of formula (Ia) may also demonstrate DPP-IV inhibitory activity.",PROSIDION LTD,BARBA OSCAR;;BELL JAMES CHARLES;;BERTRAM LISA;;DUPREE TOM;;FRY PETER;;FYFE MATTHEW;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS;;MCDONALD RUSSELL;;MORGAN TREVOR;;RASAMISON CHRYSTELLE;;SCHOFIELD KAREN;;STEWART ALAN;;SWAIN SIMON;;WITHALL DAVID,,https://lens.org/075-876-994-988-681,Patent Application,no,7,0,2,8,0,A61K31/445;;A61K31/497;;A61K31/506;;A61P3/04;;A61P3/06;;A61P3/10;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D401/12;;C07D401/14;;C07D405/14;;C07D413/14;;C07D417/14;;C07D487/04,C07D401/14;;A61K31/445;;A61K31/497;;A61K31/506;;A61P3/04;;A61P3/06;;A61P3/10;;C07D401/12;;C07D405/14;;C07D413/14;;C07D417/14,,0,0,,,,DISCONTINUED
110,EP,A4,EP 3009768 A4,133-731-360-804-857,2017-03-15,2017,EP 14810571 A,2014-06-06,ES 201330887 A;;ES 2014070468 W,2013-06-14,MACHINE FOR AIR-COOLED ABSORPTION,,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,UNIVERSITAT POLITECNICA DE CATALUNYA (2020-11-25),https://lens.org/133-731-360-804-857,Search Report,no,6,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06;;F25B37/00;;F25B39/02,,1,0,,,See also references of WO 2014198983A1,ACTIVE
111,EP,B1,EP 3147618 B1,181-584-574-956-163,2019-04-17,2019,EP 14892196 A,2014-05-14,ES 2014070400 W,2014-05-14,"HEAT ENERGY ACCUMULATOR BASED ON SOLID-LIQUID PHASE-CHANGE MATERIALS, AND METHOD FOR PRODUCING THE UNIT",,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;MORALES RUIZ SERGIO,,https://lens.org/181-584-574-956-163,Granted Patent,yes,10,0,5,5,0,F28D20/021;;F28D2020/0021;;Y02E60/14,F28D20/02;;F28D20/00,,0,0,,,,ACTIVE
112,WO,A1,WO 2014/198983 A1,195-030-033-891-356,2014-12-18,2014,ES 2014070468 W,2014-06-06,ES 201330887 A,2013-06-14,MACHINE FOR AIR-COOLED ABSORPTION,"The invention relates to the design of an air-cooled absorption machine. Said machine has a hollow design via which air can circulate inside same by forced convection, having a parallelepiped form. The air enters by suction via the sides and leaves via the upper face of the machine, where the ventilator is located. The machine comprises falling-film heat exchangers with improved designs for heat and mass transfer.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,,https://lens.org/195-030-033-891-356,Patent Application,yes,32,1,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,1,0,,,See also references of EP 3009768A4,PENDING
113,ES,B1,ES 2540123 B1,005-238-643-239-229,2016-04-29,2016,ES 201330887 A,2013-06-14,ES 201330887 A,2013-06-14,Máquina de absorción refrigerada por aire,,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDONO MARTINEZ MANUEL MIGUEL;;FARNOS BAULENAS JOAN,,https://lens.org/005-238-643-239-229,Granted Patent,no,0,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,0,0,,,,ACTIVE
114,EP,A1,EP 3147618 A1,163-029-629-851-17X,2017-03-29,2017,EP 14892196 A,2014-05-14,ES 2014070400 W,2014-05-14,"HEAT ENERGY ACCUMULATOR BASED ON SOLID-LIQUID PHASE-CHANGE MATERIALS, AND METHOD FOR PRODUCING THE UNIT","The invention relates to the design of a thermal energy storage unit that can store and recover the heat produced by an external source in the form of phase change sensible heat and latent heat by using a solid-liquid phase-change material. The phase-change material is encapsulated between two sheets, preferably metal sheets, forming a plate. A group of said plates is contained and duly organized inside a parallelepipedal casing, thereby forming the heat accumulator unit.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;MORALES RUIZ SERGIO,,https://lens.org/163-029-629-851-17X,Patent Application,yes,0,1,5,5,0,F28D20/021;;F28D2020/0021;;Y02E60/14,F28D20/02,,0,0,,,,ACTIVE
115,ES,T3,ES 2734648 T3,002-078-668-250-804,2019-12-11,2019,ES 14892196 T,2014-05-14,ES 2014070400 W,2014-05-14,Acumulador de energía térmica a base de materiales de cambio de fase sólido-líquido y método de fabricación de la unidad,"Se presenta el diseño y método de fabricación de un acumulador de energía térmica capaz de almacenar y recuperar el calor obtenido desde una fuente externa en forma de calor sensible y calor latente de cambio de fase, mediante la utilización de un matenal de cambio de fase (sólido-líquido). El material de cambio de fase está encapsulado entre dos láminas, preferiblemente metálicas, configurando una placa. Un grupo de dichas placas están contenidas y organizadas debidamente en el interior de un carcasa de forma paralelepipédica, conformando así el dispositivo acumulador de calor.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDONO MARTINEZ MANUEL MIGUEL;;MORALES RUIZ SERGIO,,https://lens.org/002-078-668-250-804,Granted Patent,no,0,0,5,5,0,F28D20/021;;F28D2020/0021;;Y02E60/14,F28D20/02;;F28D20/00,,0,0,,,,ACTIVE
116,EP,A1,EP 3009768 A1,035-480-074-223-502,2016-04-20,2016,EP 14810571 A,2014-06-06,ES 201330887 A;;ES 2014070468 W,2013-06-14,MACHINE FOR AIR-COOLED ABSORPTION,"The invention relates to the design of an air cooled absorption machine. Said machine has a hollow design via which air can circulate inside same by forced convention having a parallelepiped form. The air enters by suction via the sides and leaves via the upper face of the machine, where the ventilator is located. The machine comprises falling-film heat exchangers with improved designs for heat and mass transfer.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,UNIVERSITAT POLITECNICA DE CATALUNYA (2020-11-25),https://lens.org/035-480-074-223-502,Patent Application,yes,0,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B37/00;;F25B15/06;;F25B39/02,,0,0,,,,ACTIVE
117,EP,A4,EP 3147618 A4,055-163-944-726-784,2018-04-25,2018,EP 14892196 A,2014-05-14,ES 2014070400 W,2014-05-14,"HEAT ENERGY ACCUMULATOR BASED ON SOLID-LIQUID PHASE-CHANGE MATERIALS, AND METHOD FOR PRODUCING THE UNIT",,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;MORALES RUIZ SERGIO,,https://lens.org/055-163-944-726-784,Search Report,no,4,0,5,5,0,F28D20/021;;F28D2020/0021;;Y02E60/14,F28D20/02;;F28D20/00,,1,0,,,See also references of WO 2015173441A1,ACTIVE
118,US,A1,US 2016/0146514 A1,062-877-608-000-616,2016-05-26,2016,US 201414898206 A,2014-06-06,ES 201330887 A;;ES 2014070468 W,2013-06-14,MACHINE FOR AIR-COOLED ABSORPTION,"The invention relates to the design of an air cooled absorption machine. Said machine has a hollow design via which air can circulate inside same by forced convention having a parallelepiped form. The air enters by suction via the sides and leaves via the upper face of the machine, where the ventilator is located. The machine comprises falling-film heat exchangers with improved designs for heat and mass transfer.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,UNIVERSITAT POLITECNICA DE CATALUNYA (2015-12-15),https://lens.org/062-877-608-000-616,Patent Application,yes,31,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,0,0,,,,INACTIVE
119,CN,A,CN 105378395 A,023-185-902-022-793,2016-03-02,2016,CN 201480039839 A,2014-06-06,ES 2014070468 W;;ES 201330887 A,2013-06-14,Machine for air-cooled absorption,"The invention relates to the design of an air-cooled absorption machine. Said machine has a hollow design via which air can circulate inside same by forced convection, having a parallelepiped form. The air enters by suction via the sides and leaves via the upper face of the machine, where the ventilator is located. The machine comprises falling-film heat exchangers with improved designs for heat and mass transfer.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESUS;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDONO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,,https://lens.org/023-185-902-022-793,Patent Application,no,5,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,0,0,,,,INACTIVE
120,ES,A1,ES 2540123 A1,096-075-526-077-483,2015-07-08,2015,ES 201330887 A,2013-06-14,ES 201330887 A,2013-06-14,"Air-cooled absorption machine (Machine-translation by Google Translate, not legally binding)","The design of an air-cooled absorption machine is presented. The machine has a hollow design, through which air can circulate inside it in forced convection, having a parallelepiped shape. The air enters in aspiration by the lateral sides and leaves by the superior face of the machine, where the fan is located. The machine features improved designs of its falling film heat exchangers for heat and mass transfer. (Machine-translation by Google Translate, not legally binding)",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDONO MARTINEZ MANUEL MIGUEL;;FARNOS BAULENAS JOAN,,https://lens.org/096-075-526-077-483,Patent Application,no,4,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,0,0,,,,ACTIVE
121,ZA,B,ZA 201107445 B,035-385-392-651-531,2012-06-27,2012,ZA 201107445 A,2011-10-11,GB 0904284 A;;GB 2010050440 W,2009-03-12,COMPOUND FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;FYFE MATTHEW COLLIN THOR;;JEEVARATHNAM REVATHY PERPETUA;;PROCTER MARTIN JAMES;;SCHOFIELD KAREN LESLEY;;STEWARD ALAN JOHN WILLIAM;;SWAIN SIMONS ANDREW;;FRY PETER TIMOTHY;;GATTRELL WILLIAM;;KRULLE THOMAS MARTIN;;SAMBROOK-SMITH COLLIN PETER;;SMYTH DONALD;;STONEHOUSE DAVID FRENCH,,https://lens.org/035-385-392-651-531,Granted Patent,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,A61K/;;A61P/;;C07D/,,0,0,,,,ACTIVE
122,SG,A1,SG 174279 A1,067-183-121-034-318,2011-10-28,2011,SG 2011064441 A,2010-03-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/067-183-121-034-318,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,,,0,0,,,,PENDING
123,US,A1,US 2012/0077793 A1,147-636-608-840-409,2012-03-29,2012,US 201013255525 A,2010-03-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,Compounds for the Treatment of Metabolic Disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes.,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,PROSIDION LIMITED (2011-09-21),https://lens.org/147-636-608-840-409,Patent Application,yes,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,A61K31/4439;;A61K31/454;;A61K31/4545;;A61K31/4725;;A61K31/497;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P3/10;;A61P9/12;;C07D401/12;;C07D401/14;;C07D413/14,514/210.2;;546/194;;514/318;;546/279.1;;546/208;;514/326;;544/405;;514/255.05;;546/145;;514/307,2,2,114-223-199-230-606;;120-354-845-680-319,10.1517/13543770903153878;;19780700;;21219177;;10.1146/annurev-immunol-031210-101322,"Jones R. M. et al. Expert Opin. Ther. Patents 2009, 19 (10), 1339-1359;;Gregor, M. F., Hotamisligil, G. S. Annu. Rev. Immunol. 2011, 29, 415-445, Abstract",DISCONTINUED
124,MX,A,MX 2011009490 A,199-038-531-908-036,2011-10-11,2011,MX 2011009490 A,2010-03-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS.,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD,FYFE MATTHEW COLIN THOR;;PROCTER MARTIN JAMES;;SCHOFIELD KAREN LESLEY;;BARBA OSCAR;;KRULLE THOMAS MARTIN;;SMYTH DONALD;;GATTRELL WILLIAM;;SWAIN SIMON ANDREW;;JEEVARATNAM REVATHY PERPETUA;;SAMBROOK-SMITH COLIN PETER;;STONEHOUSE DAVID FRENCH;;FRY PETER TIMOTHY;;STEWART ALAN JOHN WILLIAM,,https://lens.org/199-038-531-908-036,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,A61K31/397;;C07D401/12;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,PENDING
125,US,B2,US 10527324 B2,024-117-421-216-61X,2020-01-07,2020,US 201414898206 A,2014-06-06,ES 201330887 A;;ES 2014070468 W,2013-06-14,Machine for air-cooled absorption,"The invention relates to the design of an air cooled absorption machine. Said machine has a hollow design via which air can circulate inside same by forced convention having a parallelepiped form. The air enters by suction via the sides and leaves via the upper face of the machine, where the ventilator is located. The machine comprises falling-film heat exchangers with improved designs for heat and mass transfer.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,UNIVERSITAT POLITECNICA DE CATALUNYA (2015-12-15),https://lens.org/024-117-421-216-61X,Granted Patent,yes,46,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06,,0,0,,,,INACTIVE
126,WO,A1,WO 2015/173441 A1,087-736-745-929-702,2015-11-19,2015,ES 2014070400 W,2014-05-14,ES 2014070400 W,2014-05-14,"HEAT ENERGY ACCUMULATOR BASED ON SOLID-LIQUID PHASE-CHANGE MATERIALS, AND METHOD FOR PRODUCING THE UNIT","The invention relates to the design and method for producing a heat energy accumulator that can store and recover the heat produced by an external source in the form of sensible heat and latent heat from a phase change, using a (solid-liquid) phase-change material. The phase-change material is encapsulated between two sheets, preferably metal sheets, forming a plate. A group of said plates is contained and duly organised inside a casing in a parallelepipedic form, thereby forming the heat accumulator device.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;MORALES RUIZ SERGIO,,https://lens.org/087-736-745-929-702,Patent Application,yes,6,1,5,5,0,F28D20/021;;F28D2020/0021;;Y02E60/14,F28D20/02,,0,0,,,,PENDING
127,EP,B1,EP 3009768 B1,161-507-276-283-250,2021-03-03,2021,EP 14810571 A,2014-06-06,ES 201330887 A;;ES 2014070468 W,2013-06-14,MACHINE FOR AIR-COOLED ABSORPTION,,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTINEZ MANUEL MIGUEL;;FARNOS BALUENAS JOAN,UNIVERSITAT POLITECNICA DE CATALUNYA (2020-11-25),https://lens.org/161-507-276-283-250,Granted Patent,yes,1,0,10,10,0,F25B39/026;;F25B37/00;;Y02B30/62;;F25B15/06;;Y02A30/27;;F25B15/06;;F25B37/00;;F25B39/026;;Y02B30/62;;Y02A30/27;;F25B15/06,F25B15/06;;F25B37/00;;F25B39/02,,0,0,,,,ACTIVE
128,MA,B1,MA 33190 B1,040-041-108-880-356,2012-04-02,2012,MA 34244 A,2011-10-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,مركبات لعلاج اضطرابات الاستقلاب,"L'invention concerne des composés thérapeutiques qui présentent une activité d'agonistes de gpr119 et sont utiles pour traiter des troubles métaboliques, y compris le diabète de type 2 (i).",PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/040-041-108-880-356,Granted Patent,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,ACTIVE
129,EP,A4,EP 2942591 A4,076-219-033-123-458,2016-11-02,2016,EP 13868352 A,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,,UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/076-219-033-123-458,Search Report,no,0,0,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,1,0,,,No further relevant documents disclosed,ACTIVE
130,PE,A1,PE 20120657 A1,117-558-959-023-145,2012-06-27,2012,PE 2011001632 A,2010-03-12,GB 0904284 A,2009-03-12,COMPUESTO PARA EL TRATAMIENTO DE TRASTORNOS METABOLICOS,"REFERIDA A UN COMPUESTO DE FORMULA I, DONDE p ES 1-2; Z ES CHR1, NR2 CUANDO p ES 2 Y, -N-CH2-FENILO SUSTITUIDO O NO CUANDO Z ES 1; R1 ES -N-(CH3)-C(O)-O-ALQUILO C2-C4, -N-(CH3)-C(O)-O-CICLOALQUILO C3-C6 DONDE EL CICLOALQUILO ES SUSTITUIDO O NO POR ALQUILO C1-C4; R2 ES -C(O)-O-ALQUILO C2-C4, -C(O)-O-CICLOALQUILO C3-C6 SUSTITUIDO O NO, ENTRE OTROS; Q ES -O-, -O-CH2, O-CH(CH3)-, -CH2-O, CH(CH3)-O-; X ES FENILO, HETEROARILO DE 5-6 MIEMBROS CON 1 O MAS HETEROATOMOS DE N, O, S; R3 Y R3a SON CADA UNO H, F, Cl, ENTRE OTROS; Y ES UN ENLACE, CH2, CHME-; R4 ES H, O PUEDE FORMAR CON Y (CUANDO Y ES -CH2-, -CHME-) UNIDO A LA POSICION * EN EL ANILLO FENILO PARA FORMAR UN HETEROCICLO DE 6 MIEMBROS FUSIONADOS QUE CONTIENE N; R5 ES BENCILO SUSTITUIDO O NO POR 1 O MAS GRUPOS F, CL, CN, METILO, ENTRE OTROS. UN COMPUESTO PREFERIDO ES ESTER ISOPROPILICO DEL ACIDO (S)-4-(5-{4-[2-AMINO-3-((S)-2-CIANOPIRROLIDIN-1-IL)-3-OXOPROPIL]-3-FLUOROFENIL}-PIRIDIN-2-ILOXIMETIL)-PIPERIDIN-1-CARBOXILICO. DICHOS COMPUESTOS SON AGONISTAS DE GPR119, UTILES EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS QUE INCLUYEN LA DIABETES TIPO II",PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;KRULLE THOMAS MARTIN;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW;;PROCTER MARTIN JAMES;;JEEVARATNAM REVATHY PERPETUA,,https://lens.org/117-558-959-023-145,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,A61K31/4439;;A61K31/454;;A61K31/4725;;A61K31/497;;A61P3/04;;A61P3/06;;A61P3/10;;C07D401/12,,0,0,,,,DISCONTINUED
131,KR,A,KR 20110133044 A,194-009-835-555-028,2011-12-09,2011,KR 20117024018 A,2010-03-12,GB 0904284 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/194-009-835-555-028,Patent Application,no,0,1,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/14;;A61K31/4523;;A61P3/00;;C07D401/12,,0,0,,,,DISCONTINUED
132,EP,A1,EP 2942591 A1,012-345-875-532-552,2015-11-11,2015,EP 13868352 A,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a sensible heat solid material for storing/recovering the heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are duly housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones located inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterised by a high melting temperature; a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature; and a middle zone containing a sensible heat solid material.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/012-345-875-532-552,Patent Application,yes,0,6,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
133,EP,B1,EP 2942591 B1,020-985-415-048-925,2020-08-05,2020,EP 13868352 A,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,,UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/020-985-415-048-925,Granted Patent,yes,7,0,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
134,ES,B1,ES 2480765 B1,023-039-642-111-910,2015-05-08,2015,ES 201232038 A,2012-12-27,ES 201232038 A,2012-12-27,Sistema de almacenamiento de energía térmica combinando material sólido de calor sensible y material de cambio de fase,,UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESUS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/023-039-642-111-910,Granted Patent,no,0,0,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
135,US,B2,US 9841243 B2,056-310-974-439-966,2017-12-12,2017,US 201314655722 A,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,Thermal energy storage system combining sensible heat solid material and phase change material,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a sensible heat solid material for storing/recovering the heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are duly housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones located inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterized by a high melting temperature; a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature; and a middle zone containing a sensible heat solid material.",UNIV POLITÉCNICA DE CATALUNYA;;UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,UNIVERSITAT POLITECNICA DE CATALUNYA (2015-09-04),https://lens.org/056-310-974-439-966,Granted Patent,yes,16,23,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D17/00;;F28D20/00;;F28D20/02;;F28F21/04,,0,0,,,,ACTIVE
136,ES,T3,ES 2828525 T3,142-552-021-125-131,2021-05-26,2021,ES 13868352 T,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,Sistema de almacenamiento de energía térmica combinando material sólido de calor sensible y material de cambio de fase,"Un sistema para el almacenamiento y recuperación de energía térmica empleando como medio al menos un material de cambio de fase (sólido-líquido) y un material sólido de calor sensible que se encargan de almacenar/recuperar el calor obtenido desde una fuente externa en forma de calor sensible y calor latente de cambio de fase. Dichos materiales están debidamente contenidos en un único tanque, en cuyo interior existen al menos dos zonas, cada una conteniendo un material diferente, y diferenciadas por el rango de temperaturas a las que son sometidas. La configuración más usada consiste en tres diferentes zonas configuradas al interior del tanque: zona caliente, en la parte superior del tanque, donde un material de cambio de fase encapsulado caracterizado por una temperatura de fusión alta está encerrado; zona fría, ubicada en la parte inferior, donde un material de cambio de fase con baja temperatura de fusión está colocado; y una zona media, que contiene un material sólido de calor sensible.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSI;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDONO MARTINEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/142-552-021-125-131,Granted Patent,no,0,0,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
137,EP,A1,EP 2406247 A1,147-339-740-533-261,2012-01-18,2012,EP 10709925 A,2010-03-12,GB 2010050440 W;;GB 0904284 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,,PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/147-339-740-533-261,Patent Application,yes,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,DISCONTINUED
138,AU,A1,AU 2010/222671 A1,088-770-526-733-692,2011-11-03,2011,AU 2010/222671 A,2010-03-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD,OSCAR BARBA;;TIMOTHY FRY PETER;;THOR FYFE MATTHEW COLIN;;WILLIAM GATTRELL;;PERPETUA JEEVARATNAM REVATHY;;MARTIN KRULLE THOMAS;;JAMES PROCTER MARTIN;;PETER SAMBROOK-SMITH COLIN;;LESLEY SCHOFIELD KAREN;;DONALD SMYTH;;WILLIAM STEWART ALAN JOHN;;FRENCH STONEHOUSE DAVID;;ANDREW SWAIN SIMON,,https://lens.org/088-770-526-733-692,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,DISCONTINUED
139,BR,A2,BR PI1013245 A2,164-899-792-647-326,2016-04-05,2016,BR PI1013245 A,2010-03-12,GB 2010050440 W;;GB 0904284 A,2009-03-12,"""composto para o tratamento de distúrbios metabólicos""",,PROSIDION LTD,STEWART ALAN JOHN WILLIAM;;SAMBROOK-SMITH COLIN PETER;;STONEHOUSE DAVID FRENCH;;SMYTH DONALD;;SCHOFIELD KAREN LESLEY;;PROCTER MARTIN JAMES;;FYRE MATTHEW COLIN THOR;;BARBA OSCAR;;FRY PETER TIMOTHY;;JEEVARATNAM REVATHY PERPETUA;;SWAIN SIMON ANDREW;;KRULLE THOMAS MARTIN;;GATTRELL WILLIAM,,https://lens.org/164-899-792-647-326,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,DISCONTINUED
140,CA,A1,CA 2754709 A1,165-171-226-717-988,2010-09-16,2010,CA 2754709 A,2010-03-12,GB 0904284 A;;GB 2010050440 W,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/165-171-226-717-988,Patent Application,no,0,0,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,A61K31/397;;C07D401/12;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,DISCONTINUED
141,CN,A,CN 102348703 A,116-308-093-936-569,2012-02-08,2012,CN 201080011554 A,2010-03-12,GB 2010050440 W;;GB 0904284 A,2009-03-12,Compounds for the treatment of metabolic disorders,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD,OSCAR BARBA;;TIMOTHY FRY PETER;;THOR FYFE MATTHEW COLIN;;WILLIAM GATTRELL;;PERPETUA JEEVARATNAM REVATHY;;MARTIN KRULLE THOMAS;;JAMES PROCTER MARTIN;;PETER SAMBROOK-SMITH COLIN;;LESLEY SCHOFIELD KAREN;;DONALD SMYTH;;WILLIAM STEWART ALAN JOHN;;FRENCH STONEHOUSE DAVID;;ANDREW SWAIN SIMON,,https://lens.org/116-308-093-936-569,Patent Application,no,3,1,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,0,0,,,,DISCONTINUED
142,US,A1,US 2016/0201995 A1,174-001-996-270-689,2016-07-14,2016,US 201314655722 A,2013-12-18,ES 201232038 A;;ES 2013070889 W,2012-12-27,Thermal energy storage system combining sensible heat solid material and phase change material,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a sensible heat solid material for storing/recovering the heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are duly housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones located inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterised by a high melting temperature; a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature; and a middle zone containing a sensible heat solid material.",UNI POLITÈCNICA DE CATALUNYA;;UNI POLITÈCNICA DE CATALUNA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JESÚS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDOÑO MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,UNIVERSITAT POLITECNICA DE CATALUNYA (2015-09-04),https://lens.org/174-001-996-270-689,Patent Application,yes,2,16,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/02;;F28D20/00;;F28F21/04,,0,0,,,,ACTIVE
143,WO,A1,WO 2010/103333 A1,182-091-143-994-804,2010-09-16,2010,GB 2010050440 W,2010-03-12,GB 0904284 A,2009-03-12,COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS,The present invention is directed to therapeutic compounds which have activity as agonists of GPR119 and are useful for the treatment of metabolic disorders including type II diabetes (I).,PROSIDION LTD;;BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,BARBA OSCAR;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KRULLE THOMAS MARTIN;;PROCTER MARTIN JAMES;;SAMBROOK-SMITH COLIN PETER;;SCHOFIELD KAREN LESLEY;;SMYTH DONALD;;STEWART ALAN JOHN WILLIAM;;STONEHOUSE DAVID FRENCH;;SWAIN SIMON ANDREW,,https://lens.org/182-091-143-994-804,Patent Application,yes,33,6,18,18,0,C07D213/64;;C07D401/12;;C07D401/14;;C07D403/14;;C07D413/14;;A61P25/00;;A61P27/02;;A61P27/16;;A61P3/00;;A61P3/04;;A61P3/06;;A61P3/08;;A61P43/00;;A61P9/10;;A61P9/12;;A61P3/10;;C07D401/14;;C07D401/12;;A61K31/4523;;C07D401/12;;C07D413/14;;C07D403/14;;C07D401/14;;C07D213/64,C07D401/12;;A61K31/397;;A61K31/4523;;A61P3/00;;C07D401/14;;C07D403/14;;C07D413/14,,5,4,041-211-316-532-650;;122-017-674-921-151;;047-842-597-267-580;;020-034-478-792-563,11733510;;10.1074/jbc.m107384200;;10.1016/s0960-894x(99)00398-4;;10476879;;10.1126/science.2171146;;2171146;;2535825;;10.2337/diabetes.38.1.44;;10.2337/diab.38.1.44,"MIRET J. J. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 6881 - 6887;;CAMPBELL R.M. ET AL., BIOORG. MED. CHEM. LETT., vol. 9, 1999, pages 2413 - 2418;;KING K. ET AL., SCIENCE, vol. 250, 1990, pages 121 - 123;;AGATEP, R. ET AL.: ""Technical Tips Online, Trends Journals"", 1998, ELSEVIER, article ""Transformation of Saccharomyces cerevisiae by the lithium acetate/single-stranded carrier DNA/polyethylene glycol (LiAc/ss-DNA/PEG) protocol"";;ZHANG HJ; WALSETH TF; ROBERTSON RP: ""Insulin secretion and cAMP metabolism in HIT cells. Reciprocal and serial passage-dependent relationships"", DIABETES, vol. 38, no. 1, January 1989 (1989-01-01), pages 44 - 8",PENDING
144,ES,A1,ES 2480765 A1,165-759-019-076-142,2014-07-28,2014,ES 201232038 A,2012-12-27,ES 201232038 A,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a solid sensible heat material for storing/recovering heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones configured inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterised by a high melting temperature a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature and a middle zone containing a solid sensible heat material.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSIO;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JESUS;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDO O MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/165-759-019-076-142,Patent Application,no,0,2,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
145,WO,A1,WO 2014/102418 A1,084-951-413-253-841,2014-07-03,2014,ES 2013070889 W,2013-12-18,ES 201232038 A,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a solid sensible heat material for storing/recovering heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones configured inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterised by a high melting temperature; a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature; and a middle zone containing a solid sensible heat material.",UNI POLITÈCNICA DE CATALUNYA,OLIVA LLENA ASENSI;;PÉREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZÁLEZ JES S;;OLIET CASASAYAS CARLES;;RODRÍGUEZ PÉREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDO O MARTÍNEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRÉS,,https://lens.org/084-951-413-253-841,Patent Application,yes,17,4,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,PENDING
146,CN,A,CN 105008840 A,119-506-920-532-143,2015-10-28,2015,CN 201380073528 A,2013-12-18,ES 2013070889 W;;ES 201232038 A,2012-12-27,THERMAL ENERGY STORAGE SYSTEM COMBINING SOLID SENSIBLE HEAT MATERIAL AND PHASE CHANGE MATERIAL,"The invention relates to a system for the storage and recovery of thermal energy, using, as its medium, at least one phase change material (solid-liquid) and a solid sensible heat material for storing/recovering heat obtained from an external source in the form of phase change latent heat and sensible heat. The aforementioned materials are housed inside a single tank containing at least two zones which are differentiated by the range of temperatures to which they are subjected, each zone containing a different material. The most common configuration consists of three different zones configured inside the tank, namely: a hot zone in the upper part of the tank, enclosing an encapsulated phase change material characterised by a high melting temperature; a cold zone housed in the lower part of the tank, containing a phase change material with a low melting temperature; and a middle zone containing a solid sensible heat material.",UNIV CATALUNYA POLITECNICA,OLIVA LLENA ASENSI;;PEREZ SEGARRA CARLOS DAVID;;RIGOLA SERRANO JOAQUIM;;CASTRO GONZALEZ JES S;;OLIET CASASAYAS CARLES;;RODRIGUEZ PEREZ IVETTE;;LEHMKUHL BARBA ORIOL;;TRIAS MIQUEL XAVI;;CAPDEVILA PARAMIO ROSER;;ALBA QUEIPO RAMIRO;;ORDO O MARTINEZ MANUEL MIGUEL;;GALIONE KLOT PEDRO ANDRES,,https://lens.org/119-506-920-532-143,Patent Application,no,7,6,11,11,0,F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14;;F28D20/026;;F28F21/04;;F28D20/0056;;F28D20/023;;F28D2020/0086;;F28D2020/006;;F28D2020/0065;;Y02E60/14,F28D20/00;;F28D20/02,,0,0,,,,ACTIVE
147,WO,A8,WO 2011/147951 A8,062-314-582-890-454,2012-03-15,2012,EP 2011058703 W,2011-05-27,GB 201008985 A;;GB 201019547 A;;GB 201103283 A,2010-05-28,CYCLOAMINO DERIVATIVES AS GPR119 AGONISTS,"Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.",PROSIDION LTD;;BARBA OSCAR;;BELL JAMES CHARLES;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;BERTRAM LISA SARAH;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS MARTIN;;MCDONALD RUSSELL WALKER;;MORGAN TREVOR;;RASAMISON CHRYSTELLE MARIE;;SCHOFIELD KAREN LESLEY;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,BARBA OSCAR;;BELL JAMES CHARLES;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;BERTRAM LISA SARAH;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS MARTIN;;MCDONALD RUSSELL WALKER;;MORGAN TREVOR;;RASAMISON CHRYSTELLE MARIE;;SCHOFIELD KAREN LESLEY;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/062-314-582-890-454,Amended Application,yes,0,0,4,8,0,A61P3/00;;A61P3/06;;A61P3/10;;C07D413/14;;C07D401/14;;C07D409/14;;C07D417/14;;C07D487/04;;C07D491/08,C07D401/14;;A61K31/454;;A61P3/10;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D491/08,,0,0,,,,PENDING
148,WO,A1,WO 2011/147951 A1,087-558-352-211-266,2011-12-01,2011,EP 2011058703 W,2011-05-27,GB 201008985 A;;GB 201019547 A;;GB 201103283 A,2010-05-28,CYCLOAMINO DERIVATIVES AS GPR119 ANTAGONISTS,"Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (la) may also demonstrate DPP-IV inhibitory activity.",PROSIDION LTD;;BARBA OSCAR;;BELL JAMES CHARLES;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;BERTRAM LISA SARAH;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS MARTIN;;MCDONALD RUSSELL WALKER;;MORGAN TREVOR;;RASAMISON CHRYSTELLE MARIE;;SCHOFIELD KAREN LESLEY;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,BARBA OSCAR;;BELL JAMES CHARLES;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;BERTRAM LISA SARAH;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS MARTIN;;MCDONALD RUSSELL WALKER;;MORGAN TREVOR;;RASAMISON CHRYSTELLE MARIE;;SCHOFIELD KAREN LESLEY;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW,,https://lens.org/087-558-352-211-266,Patent Application,yes,41,11,4,8,0,A61P3/00;;A61P3/06;;A61P3/10;;C07D413/14;;C07D401/14;;C07D409/14;;C07D417/14;;C07D487/04;;C07D491/08,C07D401/14;;A61K31/454;;A61P3/10;;C07D409/14;;C07D413/14;;C07D417/14;;C07D487/04;;C07D491/08,,5,3,078-016-257-189-686;;007-854-898-735-007;;101-195-126-039-563,10.1517/17460441.3.4.403;;23489096;;17562364;;10.1016/j.bmcl.2007.05.087;;10.1016/j.bmcl.2007.07.081;;17822893,"FYFE M C T ET AL: ""GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity"", EXPERT OPINION ON DRUG DISCOVERY, INFORMA HEALTHCARE, LONDON, GB, vol. 3, no. 4, 1 April 2008 (2008-04-01), pages 403 - 413, XP009118163, ISSN: 1746-0441, DOI: DOI:10.1517/17460441.3.4.403;;BRACKES, BIOORG. MED. CHEM. LETT., vol. 17, no. 7, 2007, pages 2005 - 2012;;PEI, J. MED. CHEM., vol. 50, no. 8, 2007, pages 1983 - 1987;;COX, BIOORG. MED. CHEM. LETT., vol. 17, no. 16, 2007, pages 4579 - 4583;;WRIGHT, BIOORG. MED. CHEM. LETT., vol. 17, no. 20, 2007, pages 5638 - 5642",PENDING
149,TW,A,TW 201209054 A,138-094-651-892-925,2012-03-01,2012,TW 100118140 A,2011-05-24,GB 201008985 A;;GB 201019547 A;;GB 201103283 A,2010-05-28,Novel compounds,"Therapeutic compounds are disclosed having the general formula (I) that are useful for the treatment of metabolic disorders, including type II diabetes. The compounds have activity as agonists of GPR119. Compounds having the stereochemistry of formula (Ia) may also demonstrate DPP-IV inhibitory activity.",PROSIDION LTD,BARBA OSCAR;;BELL JAMES CHARLES;;DUPREE TOM BANKSIA;;FRY PETER TIMOTHY;;FYFE MATTHEW COLIN THOR;;GATTRELL WILLIAM THOMAS;;JEEVARATNAM REVATHY PERPETUA;;KEILY JOHN;;KRULLE THOMAS MARTIN;;MCDONALD RUSSELL WALKER;;MORGAN TREVOR;;RASAMISON CHRYSTELLE MARIE;;SCHOFIELD KAREN LESLEY;;STEWART ALAN JOHN WILLIAM;;SWAIN SIMON ANDREW;;WITHALL DAVID MATTHEW;;BERTRAM LISA SARAH,,https://lens.org/138-094-651-892-925,Patent of Addition,no,0,0,4,8,0,A61P3/00;;A61P3/06;;A61P3/10;;C07D413/14;;C07D401/14;;C07D409/14;;C07D417/14;;C07D487/04;;C07D491/08,C07D413/14;;A61K31/506;;A61P3/06;;A61P3/10,,0,0,,,,PENDING
150,ES,U,ES 1162061 U,114-329-555-883-220,2016-08-03,2016,ES 201630916 U,2016-07-14,ES 201630916 U,2016-07-14,"Tractor wheel for bike (Machine-translation by Google Translate, not legally binding)","Wheel (1) bicycle tractor, of the type comprising a first pinion (3) with at least one first pinion (3a) in a first side (4) of the bushing (5) to be coupled to a chain (6) ) traction characterized in that it comprises a second pinion (30) with at least one second pinion (30a), which is arranged on the second side (40) of the bushing (5) to be able to be coupled to the chain (6) by means of the reversibility of the wheel (1) and change the gear ratios and/or the traction or rolling capacity of the wheel (1). (Machine-translation by Google Translate, not legally binding)",INST DE EDUCACION SECUNDARIA EMILIO CANALEJO OLMEDA,AGUILAR REY CARLA;;BARANESCU MÓNICA BIANCA;;BARBA POZO ALBA;;BELLIDO TEJADA MARIA;;CASAS ESPEJO MATÍAS;;CRUZ GÓMEZ CELIA;;DELGADO MÁRQUEZ SARA;;ESPEJO MÁRMOL FRANCISCO JOSÉ;;ESPEJO MARQUÉS Mª VICTORIA;;GÓMEZ ALGABA JUAN CARLOS;;JIMÉNEZ AGUILAR MARINA;;MÁRQUEZ BAENA FRANCISCO JAVIER;;MESA HERNÁNDEZ ESTHER;;NAVARRO PECCI ISABEL CLARA;;POLONIO RAYA ROCÍO;;PORTERO PEDRAZA MIGUEL;;RAIGÓN BELLIDO INÉS;;RÍOS RODRÍGUEZ RUBÉN;;RODRÍGUEZ POLO MARINA;;ROLDÁN CUÉLLAR SERGIO;;RUZ BARRANCO LOURDES;;SÁNCHEZ RUZ ANTONIO DAVID;;SÁNCHEZ ZAFRA MARÍA;;VAQUERO RUIZ Mª DEL MAR;;ZAFRA ESPEJO JOAQUÍN,,https://lens.org/114-329-555-883-220,Patent Application,no,0,0,2,2,0,,B60B1/00,,0,0,,,,INACTIVE
151,ES,Y,ES 1162061 Y,151-388-315-184-684,2016-10-24,2016,ES 201630916 U,2016-07-14,ES 201630916 U,2016-07-14,RUEDA TRACTORA PARA BICICLETA,,INST DE EDUCACION SECUNDARIA EMILIO CANALEJO OLMEDA,AGUILAR REY CARLA;;BARANESCU MÓNICA BIANCA;;BARBA POZO ALBA;;BELLIDO TEJADA MARIA;;CASAS ESPEJO MATÍAS;;CRUZ GÓMEZ CELIA;;DELGADO MÁRQUEZ SARA;;ESPEJO MÁRMOL FRANCISCO JOSÉ;;ESPEJO MARQUÉS Mª VICTORIA;;GÓMEZ ALGABA JUAN CARLOS;;JIMÉNEZ AGUILAR MARINA;;MÁRQUEZ BAENA FRANCISCO JAVIER;;MESA HERNÁNDEZ ESTHER;;NAVARRO PECCI ISABEL CLARA;;POLONIO RAYA ROCÍO;;PORTERO PEDRAZA MIGUEL;;RAIGÓN BELLIDO INÉS;;RÍOS RODRÍGUEZ RUBÉN;;RODRÍGUEZ POLO MARINA;;ROLDÁN CUÉLLAR SERGIO;;RUZ BARRANCO LOURDES;;SÁNCHEZ RUZ ANTONIO DAVID;;SÁNCHEZ ZAFRA MARÍA;;VAQUERO RUIZ Mª DEL MAR;;ZAFRA ESPEJO JOAQUÍN,,https://lens.org/151-388-315-184-684,Limited Patent,no,0,0,2,2,0,,B60B1/00,,0,0,,,,INACTIVE
